<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">37925</article-id><article-id pub-id-type="doi">10.7554/eLife.37925</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-112311"><name><surname>Liao</surname><given-names>Lili</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-112310"><name><surname>Liu</surname><given-names>Zongzhi Z</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-112309"><name><surname>Langbein</surname><given-names>Lauren</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3007-5287</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-112308"><name><surname>Cai</surname><given-names>Weijia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-112307"><name><surname>Cho</surname><given-names>Eun-Ah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112306"><name><surname>Na</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112305"><name><surname>Niu</surname><given-names>Xiaohua</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112304"><name><surname>Jiang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112303"><name><surname>Zhong</surname><given-names>Zhijiu</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-122581"><name><surname>Cai</surname><given-names>Wesley L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-122584"><name><surname>Jagannathan</surname><given-names>Geetha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66328"><name><surname>Dulaimi</surname><given-names>Essel</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-122582"><name><surname>Testa</surname><given-names>Joseph R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66333"><name><surname>Uzzo</surname><given-names>Robert G</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112302"><name><surname>Wang</surname><given-names>Yuxin</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-100998"><name><surname>Stark</surname><given-names>George R</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-5259"><name><surname>Sun</surname><given-names>Jianxin</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112301"><name><surname>Peiper</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-112300"><name><surname>Xu</surname><given-names>Yaomin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3752-4006</contrib-id><email>yaomin.xu@vanderbilt.edu</email><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-38365"><name><surname>Yan</surname><given-names>Qin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4077-453X</contrib-id><email>qin.yan@yale.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-111654"><name><surname>Yang</surname><given-names>Haifeng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0892-9055</contrib-id><email>Haifeng.yang@jefferson.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Pathology, Anatomy and Cell Biology</institution><institution>Thomas Jefferson University</institution><addr-line><named-content content-type="city">Pennsylvania</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Pathology</institution><institution>Yale University</institution><addr-line><named-content content-type="city">Connecticut</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Fox Chase Cancer Center</institution><addr-line><named-content content-type="city">Pennsylvania</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Health Sciences Research</institution><institution>Mayo Clinic</institution><addr-line><named-content content-type="city">Minnesota</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Gastrointestinal Surgery</institution><institution>The Sixth Affiliated Hospital of Guangzhou Medical University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Sidney Kimmel Cancer Center</institution><institution>Thomas Jefferson University</institution><addr-line><named-content content-type="city">Pennsylvania</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Department of Cancer Biology</institution><institution>Lerner Research Institute, Cleveland Clinic</institution><addr-line><named-content content-type="city">Ohio</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Department of Medicine</institution><institution>Thomas Jefferson University</institution><addr-line><named-content content-type="city">Pennsylvania</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">Department of Biostatistics</institution><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Tennessee</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution content-type="dept">Department of Biomedical Informatics</institution><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Tennessee</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davidson</surname><given-names>Irwin</given-names></name><role>Reviewing Editor</role><aff><institution>Institut de Génétique et de Biologie Moléculaire et Cellulaire</institution><country>France</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Settleman</surname><given-names>Jeffrey</given-names></name><role>Senior Editor</role><aff><institution>Calico Life Sciences</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>25</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e37925</elocation-id><history><date date-type="received" iso-8601-date="2018-04-27"><day>27</day><month>04</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-10-22"><day>22</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Liao et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Liao et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-37925-v3.pdf"/><abstract><p>Whereas <italic>VHL</italic> inactivation is a primary event in clear cell renal cell carcinoma (ccRCC), the precise mechanism(s) of how this interacts with the secondary mutations in tumor suppressor genes, including <italic>PBRM1</italic>, <italic>KDM5C</italic>/<italic>JARID1C</italic>, <italic>SETD2</italic>, and/or <italic>BAP1</italic>, remains unclear. Gene expression analyses reveal that VHL, PBRM1, or KDM5C share a common regulation of interferon response expression signature. Loss of HIF2α, PBRM1, or KDM5C in <italic>VHL-/-</italic>cells reduces the expression of interferon stimulated gene factor 3 (ISGF3), a transcription factor that regulates the interferon signature. Moreover, loss of SETD2 or BAP1 also reduces the ISGF3 level. Finally, ISGF3 is strongly tumor-suppressive in a xenograft model as its loss significantly enhances tumor growth. Conversely, reactivation of ISGF3 retards tumor growth by PBRM1-deficient ccRCC cells. Thus after <italic>VHL</italic> inactivation, HIF induces ISGF3, which is reversed by the loss of secondary tumor suppressors, suggesting that this is a key negative feedback loop in ccRCC.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>kidney cancer</kwd><kwd>VHL</kwd><kwd>PBRM1</kwd><kwd>KDM5C</kwd><kwd>BAP1</kwd><kwd>ISGF3</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01 CA155015</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Haifeng</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA056036</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Haifeng</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-16-1-0326</award-id><principal-award-recipient><name><surname>Yan</surname><given-names>Qin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Major secondary tumor suppressors in kidney cancer are required to maintain the activity of a tumor suppressive transcription factor after the loss of the primary tumor suppressor VHL.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Kidney cancer is among the top ten cancers, both in incidence and mortality in both men and women. Inactivation of the <italic>VHL</italic> tumor suppressor gene is a causal event in the pathogenesis of clear cell Renal Cell Carcinoma (ccRCC), the most frequent subtype of kidney cancer. Approximately 70 – 80% of ccRCC are sporadic tumors that harbor biallelic inactivation of <italic>VHL</italic> (<xref ref-type="bibr" rid="bib39">Linehan et al., 2004</xref>). In the rare disease of hereditary kidney cancer, germline <italic>VHL</italic> mutation leads to early-onset bilateral kidney tumors. Biochemically, the protein product of the <italic>VHL</italic> tumor suppressor gene pVHL acts as the substrate recognition module of an E3 ubiquitin ligase complex. This complex targets the α subunits of the heterodimeric transcription factor Hypoxia-Inducible Factor (HIF) for poly-ubiquitylation and proteasomal degradation (<xref ref-type="bibr" rid="bib74">Zhang and Yang, 2012</xref>). When HIFα is hydroxylated on either of two prolyl residues by members of the EglN family (also called PHDs or HPHs) under normal oxygen tension, it is recognized by pVHL. Without pVHL, HIFα protein accumulates and activates the hypoxia response transcriptional program. This constitutively active HIF subsequently drives ccRCC tumorigenesis and tumor growth (<xref ref-type="bibr" rid="bib35">Kaelin, 2005</xref>). Interestingly, HIF targets include both tumor-promoting and tumor-suppressive genes, but its overall activity is potently oncogenic (<xref ref-type="bibr" rid="bib75">Zhang et al., 2013</xref>).</p><p>Restoration of pVHL in <italic>VHL-/-</italic> ccRCC cells suppresses their ability to form tumors in immune-compromised mice, while stabilization of HIF2α overrides the effect of pVHL (<xref ref-type="bibr" rid="bib37">Kondo et al., 2002</xref>). Conversely, HIF2α suppression in <italic>VHL</italic>-/- ccRCC cells cripples their ability to form tumors (<xref ref-type="bibr" rid="bib76">Zimmer et al., 2004</xref>). The current standard of care for metastatic ccRCC focuses on inhibiting the VEGF receptor, yet drug resistance eventually develops in most cases. Thus it is urgent to identify new drug targets that operate in a high percentage of RCC tumors, with the expectation that the dual actions on VEGFR and a new target might prevent drug resistance.</p><p>Most types of solid tumors harbor multiple, sometimes dozens of mutations, in cancer genes to establish the hallmarks of cancer (<xref ref-type="bibr" rid="bib25">Hanahan and Weinberg, 2011</xref>; <xref ref-type="bibr" rid="bib64">Vogelstein et al., 2013</xref>). In addition to <italic>VHL</italic>, several frequently mutated genes were identified in sporadic ccRCC. Varela et al. reported that 41% of ccRCC tumors had inactivating mutations in the <italic>PBRM1</italic> gene. PBRM1 is a specificity subunit of the SWI/SNF chromatin-remodeling complex (<xref ref-type="bibr" rid="bib63">Varela et al., 2011</xref>). The high mutation rate of <italic>PBRM1</italic> in ccRCC has been confirmed by multiple studies, together with mutations in other genes such as <italic>BAP1</italic>, <italic>SETD2</italic>, <italic>KDM5C</italic>/<italic>JARID1C</italic>, <italic>PTEN</italic> and <italic>UTX</italic> (<xref ref-type="bibr" rid="bib17">Dalgliesh et al., 2010</xref>; <xref ref-type="bibr" rid="bib23">Guo et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Peña-Llopis et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Cancer Genome Atlas Research Network, 2013</xref>; <xref ref-type="bibr" rid="bib56">Sato et al., 2013</xref>). However, the mutation rates of the other genes are much lower than that of <italic>PBRM1</italic> (<xref ref-type="bibr" rid="bib38">Liao et al., 2015</xref>).</p><p>Multiple lines of evidence suggest that <italic>PBRM1</italic> is a key tumor suppressor. Its mutations are predominantly inactivating in both alleles. PBRM1 suppression causes changes in pathways regulating chromosome instability and cell proliferation (<xref ref-type="bibr" rid="bib63">Varela et al., 2011</xref>). Like <italic>VHL</italic> mutations, many <italic>PBRM1</italic> mutations occur early in tumorigenesis, unlike the other secondary mutations (<xref ref-type="bibr" rid="bib20">Gerlinger et al., 2012</xref>). Recently a <italic>PBRM1</italic> germline mutation was reported to predispose patients to ccRCC (<xref ref-type="bibr" rid="bib6">Benusiglio et al., 2015</xref>). PBRM1 was also found to amplify a HIF signature (<xref ref-type="bibr" rid="bib19">Gao et al., 2017</xref>) and genetic ablation of both <italic>Vhl</italic> and <italic>Pbrm1</italic> in mouse kidneys leads to ccRCC while single loss fails to do so (<xref ref-type="bibr" rid="bib43">Nargund et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Gu et al., 2017</xref>).</p><p>KDM5C/JARID1C is a histone demethylase that removes methyl groups from tri-methylated lysine four on histone H3 (H3K4me3). H3K4me3 is a histone mark that is tightly linked to actively transcribed genes (<xref ref-type="bibr" rid="bib4">Barski et al., 2007</xref>). <italic>KDM5C</italic> mutations occur in 3–7% of ccRCC tumors (<xref ref-type="bibr" rid="bib63">Varela et al., 2011</xref>; <xref ref-type="bibr" rid="bib17">Dalgliesh et al., 2010</xref>; <xref ref-type="bibr" rid="bib10">Cancer Genome Atlas Research Network, 2013</xref>; <xref ref-type="bibr" rid="bib56">Sato et al., 2013</xref>). Its mutations are mostly subclonal and happen later during tumor development (<xref ref-type="bibr" rid="bib20">Gerlinger et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Gerlinger et al., 2014</xref>). HIF increases KDM5C levels and activity, and the overall level of H3K4me3 is elevated when KDM5C is suppressed in <italic>VHL</italic>-defective kidney cancer cells (<xref ref-type="bibr" rid="bib45">Niu et al., 2012</xref>). In addition, evidence suggests that HIF-induced KDM5C is tumor-suppressive, and this constitutes a negative feedback loop in regard to tumor growth (<xref ref-type="bibr" rid="bib45">Niu et al., 2012</xref>).</p><p>SETD2 is a histone-modifying enzyme that tri-methylates histone H3 at Lysine 36 (H3K36me3). It is mutated in 10 – 15% of ccRCC tumors (<xref ref-type="bibr" rid="bib17">Dalgliesh et al., 2010</xref>; <xref ref-type="bibr" rid="bib10">Cancer Genome Atlas Research Network, 2013</xref>; <xref ref-type="bibr" rid="bib56">Sato et al., 2013</xref>; <xref ref-type="bibr" rid="bib24">Hakimi et al., 2013</xref>). It is also located on chromosome 3 p like <italic>VHL</italic> and <italic>PBRM1. SETD2</italic> mutations are subclonalin ccRCC tumors (<xref ref-type="bibr" rid="bib20">Gerlinger et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Gerlinger et al., 2014</xref>; <xref ref-type="bibr" rid="bib55">Sankin et al., 2014</xref>), and are associated with worse patient survival (<xref ref-type="bibr" rid="bib24">Hakimi et al., 2013</xref>). SETD2 deficiency was reported to be associated with alternative splicing and transcriptional repression (<xref ref-type="bibr" rid="bib66">Wagner and Carpenter, 2012</xref>). Indeed, <italic>SETD2</italic> mutations in ccRCC tumors are associated with changes in chromatin accessibility and DNA methylation (<xref ref-type="bibr" rid="bib9">Buck et al., 2014</xref>) or widespread RNA processing defects (<xref ref-type="bibr" rid="bib58">Simon et al., 2014</xref>). Recently, SETD2 was shown to regulate interferon signaling by methylating STAT1 (<xref ref-type="bibr" rid="bib12">Chen et al., 2017</xref>), and to maintain mitosis and cytokinesis through methylating α-tubulin (<xref ref-type="bibr" rid="bib47">Park et al., 2016</xref>). The relevance of these SETD2 functions to tumor suppression in ccRCC remains to be elucidated.</p><p>Like KDM5C and SETD2, BAP1 is also a histone modifying enzyme. <italic>BAP1 </italic>is inactivated in 10 – 15% of ccRCC (<xref ref-type="bibr" rid="bib23">Guo et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Peña-Llopis et al., 2012</xref>). The <italic>BAP1</italic> gene is located on chromosome 3 at band 3p21, which is very close to the <italic>PBRM1</italic> gene. As with <italic>VHL</italic>, <italic>PBRM1</italic> and <italic>SETD2</italic>, biallelic inactivation of <italic>BAP1</italic> via mutation and loss of heterozygosity fit a two-hit tumor suppressor profile. Germline mutations of BAP1 predispose patients to ccRCC, uveal melanomas, mesothelioma, lung adenocarcinoma, meningioma, breast carcinoma and paraganglioma (<xref ref-type="bibr" rid="bib1">Abdel-Rahman et al., 2011</xref>; <xref ref-type="bibr" rid="bib65">Wadt et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Cheung et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Pilarski et al., 2014</xref>). Loss of BAP1 is associated with worse patient survival in ccRCC and seems to be mutually exclusive with<italic>PBRM1</italic> mutations (<xref ref-type="bibr" rid="bib33">Joseph et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Joseph et al., 2016</xref>). BAP1 protein was reported to form a complex with host cell factor-1 (HCF-1) and promotes DNA double-strand break repair (<xref ref-type="bibr" rid="bib70">Yu et al., 2010</xref>; <xref ref-type="bibr" rid="bib71">Yu et al., 2014</xref>). It also forms a complex with ASXL1 which is essential for its ability to deubiquitinate histone H2A on lysine 119, and this function regulates cell proliferation (<xref ref-type="bibr" rid="bib18">Daou et al., 2015</xref>). Recently it was shown to regulate IP3R3-mediated Ca<sup>2+</sup> to mitochondria to suppress cell transformation (<xref ref-type="bibr" rid="bib7">Bononi et al., 2017</xref>). How these functions contribute to its tumor suppressor role in ccRCC is unclear.</p><p>These secondary tumor suppressors each have their own distinct biological functions and are associated with different prognoses for the patients, and yet they all regulate chromatin biology. Thus, we investigated whether they share a common tumor suppressor pathway in this study.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Interferon (IFN)-responsive genes are upregulated by PBRM1</title><p>To determine how the suppression of PBRM1 changes the transcriptome of ccRCC cells, we used shRNA to stably knock down the expression of PBRM1 in <italic>VHL+/+</italic> and <italic>VHL-/-</italic> 786-O cells. Then, we used Illumina HumanHT-12_V4 microarrays to compare gene expression between cells expressing a control shRNA (SCR) and PBRM1 shRNA-94. PBRM1 loss in <italic>VHL-/-</italic> cells elicited a higher number of transcriptional changes than in <italic>VHL+/+</italic> cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In addition, in <italic>VHL-/-</italic> cells, the transcriptional responses to PBRM1 depletion or VHL re-expression shared a group of gene targets (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). This is consistent with the previous observation that PBRM1 loss amplifies a HIF signature (<xref ref-type="bibr" rid="bib19">Gao et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Nargund et al., 2017</xref>). Gene Ontology (GO) pathway analysis of the shared genes revealed that type I IFN signaling pathway and response to virus are commonly affected (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Gene Sets Enrichment Analysis (GSEA) confirmed that the expression signature of interferon alpha response was negatively correlated with PBRM1 suppression (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Gene expression analysis revealed the reduced expression of IFN-responsive genes after PBRM1 loss (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>IFN-responsive genes were downregulated by VHL and upregulated by PBRM1.</title><p>(<bold>A</bold>) Venn diagram showing that PBRM1 loss had greater impact on transcriptome in <italic>VHL-/-</italic> cells than that in <italic>VHL+/+</italic> cells; (<bold>B</bold>) Venn diagram showing the overlap of genes downregulated by VHL and upregulated by PBRM1 in 786-O cells. <italic>P-</italic>values were calculated with hypogeometric probability. (<bold>C</bold>) Enriched gene ontology (GO) analysis of genes regulated both by VHL and PBRM1. (<bold>D</bold>) GSEA analysis of genes upregulated by PBRM1. (<bold>E</bold>) Heatmap showing the expression of IFN-responsive genes after PBRM1 knockdown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig1-v3.tif"/></fig></sec><sec id="s2-2"><title>IFN-responsive genes are also maintained by KDM5C</title><p>KDM5C is a histone-modifying enzyme that is frequently mutated in ccRCC. In order to learn how the loss of KDM5C impacts the transcriptome of ccRCC cells, we stably knocked down the expression of KDM5C in <italic>VHL+/+</italic> and <italic>VHL-/-</italic> 786-O cells. Then we compared gene expression between cells expressing a control shRNA (SCR) and KDM5C shRNA-60 with the methods described above. Similar to PBRM1 suppression, KDM5C loss in <italic>VHL-/-</italic> cells elicited greater transcriptional changes than that in <italic>VHL+/+ </italic>cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We also observed that in <italic>VHL-/-</italic> cells, transcriptional responses to KDM5C depletion or VHL re-expression shared a group of gene targets (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). This is consistent with the previous observation that HIF activates KDM5C and this constitutes a negative feedback loop (<xref ref-type="bibr" rid="bib45">Niu et al., 2012</xref>). GO pathway analysis, GSEA, and gene expression data confirmed that the type I IFN signaling pathway, the expression signature of interferon alpha response, and the IFN-responsive genes were impacted by KDM5C loss (<xref ref-type="fig" rid="fig2">Figure 2C–E</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>IFN-responsive genes were downregulated by VHL and upregulated by KDM5C.</title><p>(<bold>A</bold>) Venn diagram showing that KDM5C loss had greater impact on transcriptome in <italic>VHL-/-</italic> cells than that in <italic>VHL+/+</italic> cells; (<bold>B</bold>) Venn diagram showing the overlap of genes downregulated by VHL and upregulated by KDM5C in 786-O cells. <italic>P-</italic>values were calculated with hypogeometric probability. (<bold>C</bold>) Enriched gene ontology (GO) analysis of genes regulated both by VHL and KDM5C. (<bold>D</bold>) GSEA analysis of genes upregulated by KDM5C. (<bold>E</bold>) Heatmap showing the expression of IFN-responsive genes after KDM5C knockdown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig2-v3.tif"/></fig></sec><sec id="s2-3"><title>Suppression of KDM5C and PBRM1 have similar impacts on gene expression</title><p>Since the suppression of either PBRM1 or KDM5C in <italic>VHL-/-</italic> 786-O cells significantly impacted the type I IFN signaling pathway (<xref ref-type="fig" rid="fig1">Figures 1B</xref> and <xref ref-type="fig" rid="fig2">2B</xref>), and the gene lists largely overlapped (<xref ref-type="fig" rid="fig1">Figures 1E</xref> and <xref ref-type="fig" rid="fig2">2E</xref>), we compared the transcriptional responses to the loss of PBRM1 or KDM5C. The vast majority of the upregulated genes and downregulated genes after suppression of PBRM1 or KDM5C were shared (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The GO pathway analysis of the shared genes that are suppressed by PBRM1 or KDM5C did not reveal any significantly impacted pathway, but the shared induced genes showed that “response to virus” was significantly enriched (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The heat map shows the commonly affected genes (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). To confirm that the transcriptional response was not the result of the off-target effects of a single shRNA, we suppressed the expression of PBRM1 or KDM5C with two shRNA constructs each. Then we measured the expression of selected IFN-responsive genes with RT-PCR, and found that the transcriptional changes in <italic>IL6</italic>, <italic>ISG20</italic>, <italic>IL8</italic>, <italic>ARPC4</italic>, <italic>GAS6</italic>, and <italic>STMN3</italic> were consistent (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). To ensure that our observation is not confined to just one cell line, we performed similar experiments in Ren-02 cells, another VHL-/- ccRCC cell line. Again, the suppression of PBRM1 or KDM5C with different shRNA constructs produced consistent transcriptional changes (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), suggesting that PBRM1 loss or KDM5C loss elicits similar transcriptional responses.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Suppression of KDM5C or PBRM1 had similar impact on gene expression in ccRCC cells.</title><p>(<bold>A</bold>) Venn diagrams showing the overlaps of genes whose expression are affected by PBRM1 or KDM5C losses in 786-O. The p-value significance of the overlap in a Venn diagram was calculated using hypergeometric test in R; (<bold>B</bold>) Enriched gene ontology (GO) analysis of genes regulated both by PBRM1 and KDM5C; (<bold>C</bold>) Heat map of shared gene targets by PBRM1 and KDM5C; (<bold>D-E</bold>) Examination of mRNA expression of individual genes by RT-qPCR in 786-O (<bold>D</bold>) and Ren-02 (<bold>E</bold>) after PBRM1 or KDM5C was suppressed by shRNA. The p-value significance in the bar graph was calculated with two-tailed student <italic>t</italic> test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001. analysis of the shared genes that are suppressed by PBRM1 or KDM5C did not reveal any significantly impacted pathway, but the shared induced genes showed that ‘response to virus’ was significantly enriched (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The heat map shows the commonly affected genes (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). To confirm that the transcriptional response was not the result of the off-target effects of a single shRNA, we suppressed the expression of PBRM1 or KDM5C with two shRNA constructs each. Then, we measured the expression of selected IFN-responsive genes with RT-PCR, and found that the transcriptional changes in <italic>IL6</italic>, <italic>ISG20</italic>, <italic>IL8</italic>, <italic>ARPC4</italic>, <italic>GAS6</italic>, and <italic>STMN3</italic> were consistent (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). To ensure that our observation is not confined to just one cell line, we performed similar experiments in Ren-02 cells, another <italic>VHL-/-</italic> ccRCC cell line. Again, the suppression of PBRM1 or KDM5C with different shRNA constructs produced consistent transcriptional changes (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), suggesting that PBRM1 loss or KDM5C loss elicits similar transcriptional responses.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig3-v3.tif"/></fig></sec><sec id="s2-4"><title>PBRM1 interacts with KDM5C</title><p>Since loss of PBRM1 or KDM5C elicited very similar transcriptional responses, we examined whether these two proteins exist in one complex. When both proteins are expressed in HEK293T cells, immunoprecipitation of either protein pulled down the other (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In addition, over-expressed Flag-PBRM1 was able to immunoprecipitate endogenous KDM5C protein and other PBAF subunits (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Flag-KDM5C was able to pull down endogenous PBRM1 along with BRG1 and BAF170, the catalytic and structural subunits of PBAF complex respectively (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Interestingly, it did not significantly co-IP BRD7 or BAF57, unlike that of Flag-PBRM1 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), suggesting that Flag-KDM5C pulled down a partial PBAF complex. Moreover, the endogenous PBRM1 also pulled down the endogenous KDM5C in human embryonic kidney (HEK) 293T cells along with the other PBAF subunits (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), suggesting that their interaction is not an artifact due to over-expression. PBRM1 truncation analysis suggested that its C-terminus, possibly the HMG domain, is important for KDM5C interaction (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). These results suggest that two proteins exist in one protein complex, and this could be the mechanism that they regulate the expression of similar target genes.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>PBRM1 interacts with KDM5C.</title><p>(<bold>A</bold>) The indicated plasmids were transfected into HEK293T cells. Immunoprecipitations were performed followed by immunoblots with the indicated antibodies. Flag-PBRM1 (<bold>B</bold>) or Flag-KDM5C (<bold>C</bold>) was transfected into HEK293T cells. Immunoprecipitations were performed followed by immunoblots with the indicated antibodies. (<bold>D</bold>) HEK293T cell lysate was immunoprecipitated with indicated antibodies followed by immunoblots with the indicated antibodies. (<bold>E</bold>) A schematic diagram of PBRM1 constructs used for KDM5C interaction analysis (top). The indicated plasmids were transfected into HEK293T cells. Immunoprecipitations were performed followed by immunoblots with the indicated antibodies (bottom).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig4-v3.tif"/></fig></sec><sec id="s2-5"><title>VHL, PBRM1 and KDM5C share the regulation of ISGF3</title><p>Since loss of both PBRM1 and KDM5C triggered greater transcriptional responses in <italic>VHL-/-</italic> cells than that in <italic>VHL+/+</italic> cells, and HIF transcriptionally interacts with PBRM1 and KDM5C (<xref ref-type="bibr" rid="bib19">Gao et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Niu et al., 2012</xref>), we wondered whether VHL-regulated genes overlapped with PBRM1 and KDM5C-regulated genes. Comparison of the transcriptional changes revealed that a group of 27 genes was suppressed by VHL but induced by PBRM1 or KDM5C (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), and these genes were the interferon-responsive genes (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). A GO pathway analysis showed that these shared genes belong to the type I interferon signaling pathway (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>HIF, PBRM1 and KDM5C are required for the expression and activity of ISGF3.</title><p>A Venn diagram showing the overlaps of genes whose expression was affected by VHL, PBRM1 or KDM5C losses in 786-O cells. The p-value significance of the overlap in a venn diagram was calculated using hypergeometric test in R; (<bold>B</bold>) Heat map of shared gene targets by VHL, PBRM1 and KDM5C; (<bold>C</bold>) Enriched gene ontology (GO) analysis of genes regulated both by VHL, PBRM1 and KDM5C; (<bold>D</bold>) Western blots with the indicated antibodies in 786-O cell SDS-solubilized whole cell lysates with HIF2α, PBRM1 or KDM5C suppressed by shRNA; (<bold>E</bold>) Examination of mRNA expression of individual genes by RT-qPCR in 786-O cells after PBRM1 or KDM5C suppression by shRNA; (<bold>F</bold>) Western blots with the indicated antibodies in Ren-02 cell SDS-solubilized whole cell lysates with HIF2α, PBRM1 or KDM5C suppressed by shRNA. The p-value significance in the bar graph was calculated with two-tailed student t test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Over-expression of HIF2α in VHL+/+ccRCC cells increases ISGF3 levels and activity.</title><p>Empty vector or HA-HIF2<bold>α</bold>dpa (a stable and constitutively active HIF2<bold>α</bold> mutant) was transiently transfected into VHL-proficient Caki-1 or Ren-01 ccRCC cells. The SDS cellular lysates were subjected to SDS-PAGE then blotted with the indicated antibodies.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig5-figsupp1-v3.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Suppression of HIF1α does not reduce ISGF3 protein level or function in RCC4 cells.</title><p>HIF1α was stably suppressed by shRNA constructs in RCC4 cells and the lysates were immunoblotted with indicated antibodies.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig5-figsupp2-v3.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>The reduced expression of ISGF3 targets in Ren-02 cells after suppression of PBRM1 or KDM5C.</title><p>Examination of mRNA expression of individual genes by RT-qPCR in Ren-02 cells after PBRM1 or KDM5C suppression by shRNA. The p-value significance in the bar graph was calculated with two-tailed student t test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig5-figsupp3-v3.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>The ISGF3 is mostly unphosphorylated in 786-O ccRCC cells.</title><p>786-O cells expressing SCR, PBRM1-sh94 (<bold>A</bold>) or KDM5C-sh60 (<bold>B</bold>) were mock treated or treated with interferon alpha for two hours. The SDS cellular lysates were subjected to SDS-PAGE then blotted with the indicated antibodies.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig5-figsupp4-v3.tif"/></fig></fig-group><p>Close inspection of these genes suggested that they are the transcriptional targets of interferon stimulated gene factor 3 (ISGF3). ISGF3 is a heterotrimeric transcription factor composed of STAT1, STAT2, and IRF9, and it can be activated either by interferon-induced posttranslational modifications or increased protein levels (<xref ref-type="bibr" rid="bib13">Cheon et al., 2013</xref>). Since these genes are suppressed by VHL, components of ISGF3 might be HIF targets. To test this, we suppressed HIF2α expression with two shRNA constructs in 786-O cells, then examined the expression of the ISGF3 components. After HIF2α suppression, the protein levels of IRF9 and STAT2 were reduced while the STAT1 protein level did not change (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Conversely, transient expression of a stable and active form of HIF2α in <italic>VHL+/+</italic>ccRCC cell lines, Caki-1 and Ren-01, slightly increased the expression levels of ISGF3 and its targets (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Suppression of HIF1α did not reduce ISGF3 protein level or function in RCC4 cells (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). To test whether PBRM1 and KDM5C also had similar effects on ISGF3, we examined its components in 786-O cells with PBRM1 and KDM5C knocked down with various shRNA constructs. In PBRM1 knockdown cells, the protein levels of IRF9 and STAT2 were lower compared to control (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). In KDM5C knockdown cells, the protein level of STAT2 was lower (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Consistent with this, the expression of ISGF3 target genes were significantly reduced in 786-O cells after PBRM1 or KDM5C suppression (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>To ensure that this observation is not confined to just one ccRCC cell line, we knocked down HIF2α, PBRM1 or KDM5C in another VHL-deficient ccRCC cell line, Ren-02. After HIF2α suppression, all three subunits of ISGF3 showed reduced expression (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). After PBRM1 or KDM5C suppression, the protein levels of IRF9 and STAT2 dropped (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Consistent with this, the expression of ISGF3 target genes was significantly reduced in Ren-02 cells after PBRM1 or KDM5C suppression (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>).</p><p>ISGF3 can be activated by either interferon-induced phosphorylation on STAT1 and STAT2 or increased unphosphorylated protein levels (<xref ref-type="bibr" rid="bib13">Cheon et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Borden et al., 2007</xref>). To determine the phosphorylation status of ISGF3, we used interferon α to stimulate 786-O cells with or without PBRM1 (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4A</xref>) or KDM5C (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4B</xref>) knocked down and found that the ISGF3 was mostly unphosphorylated. This suggests that the elevated protein levels of ISGF3 components are responsible for the enhanced activity of ISGF3.</p></sec><sec id="s2-6"><title>SETD2 and BAP1 also regulate the expression and function of ISGF3</title><p>A recent report suggested that SETD2 promotes ISGF3 activity through methylating STAT1 after interferon stimulation (<xref ref-type="bibr" rid="bib12">Chen et al., 2017</xref>). This prompted us to examine whether the remaining major tumor suppressors in ccRCC, SETD2 and BAP1, also regulate ISGF3 in <italic>VHL-/-</italic>ccRCC cells. We knocked down the expression of SETD2 and BAP1 with shRNA constructs in Ren-02 cells and observed significant down-regulation of IRF9 and STAT2 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). In addition, we observed reduced expression of PLSCR1 and MX1, two ISGF3 targets. BAP1 re-expression in a Ren-02 BAP1 knockdown (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, left) or knockout clone (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, right) generated by CRISPR/Cas9 increased the protein levels of STAT2, IRF9 and PLSCR1, suggesting that BAP1’s impact on ISGF3 is specific. To ensure that this effect is not confined to one cell line, we knocked down the expression of BAP1 or SETD2 in RCC4 and BAP1 in A498 cells (A498 has an inactivating mutation in <italic>SETD2</italic> so it is not suitable for SETD2 analysis), two additional VHL-deficient ccRCC cell lines. Their suppression also led to the reduced expression of IRF9, STAT2, PLSCR1 and MX1 (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). Again, the impact of BAP1 loss in A498 cells was reversed by BAP1 re-expression (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). In order to further examine the impact of BAP1 on ISGF3 expression and activity, we expressed GFP, wild type BAP1, or BAP1 with tumor-derived mutations (N78S or G185R) in BAP1 null ccRCC cell lines UMRC2 and UMRC6. Expression of wild type or N78S BAP1 clearly increased ISGF3 protein levels and its activity in these cells, while the G185R mutant failed to do so (<xref ref-type="fig" rid="fig6">Figure 6F and G</xref>). Thus SETD2 and BAP1 also are required to maintain the expression and function of ISGF3 in multiple VHL-deficient ccRCC cell lines. As a ccRCC tumor-derived mutation in BAP1 disrupted this function in both BAP1-null cells, it suggests that the regulation of ISGF3 is important to BAP1’s tumor suppressor function.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>BAP1 and SETD2 are required for the expression and activity of ISGF3.</title><p>SDS-solubilized whole cell lysates of Ren-02 cells expressing control shRNA or shRNA against BAP1 or SETD2 were blotted with the indicated antibodies.(<bold>B</bold>) Control vector expressing GFP or BAP1 were stably transfected into Ren-02 cells expressing BAP1-sh74 (left). The BAP1 plasmid carries silent mutations against BAP1-sh74 to cancel the effect of shRNA. Control vector expressing GFP or BAP1 were transiently transfected into a Ren-02 clone with BAP1 knocked out by CRISPR/Cas9 (right). The SDS-solubilized whole cell lysates were blotted with the indicated antibodies. C-D) SDS-solubilized whole cell lysates of RCC4 cells (<bold>C</bold>) or A498 cells (<bold>D</bold>) expressing the indicated shRNA constructs were blotted with the indicated antibodies. The knockdown efficiency of SETD2 was measured with RT-PCR in panels A and C. (<bold>E</bold>). Control vector expressing GFP or BAP1 with silent mutations were stably transfected into A498 cells expressing BAP1-sh74. BAP1-null UMRC2 (<bold>F</bold>) or UMRC6 (<bold>G</bold>) ccRCC cells were stably transfected with indicated plasmids. The SDS-solubilized whole cell lysates were blotted with the indicated antibodies.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Suppression of SETD2 expression by western blot.</title><p>Lysates from Ren-02 cells stably expressed indicated shRNA constructs were immunoblotted with indicated antibodies.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig6-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-7"><title>ISGF3 is tumor suppressive in a xenograft model</title><p>ISGF3 is known to be involved in the DNA damage response, response to immunotherapies and, canonically, the response to viral infection (<xref ref-type="bibr" rid="bib8">Borden et al., 2007</xref>). There is no report showing its direct involvement in regulating tumorigenesis or tumor growth. Since ISGF3 is activated by HIF and suppressed after the loss of PBRM1, KDM5C, SETD2 or BAP1, it may function as the executioner of a negative feedback loop that potently opposes tumor growth. To test this, we first confirmed that IRF9-sh69 shRNA construct successfully downregulated IRF9 expression (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Suppression of IRF9 did not significantly change cell growth in culture (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). We injected the same number of 786-O cells expressing control shRNA (SCR) or IRF-sh69 into the flanks of nude mice. The 786-O cells with IRF9 suppression produced much larger tumors than the control cells (<xref ref-type="fig" rid="fig7">Figure 7C and D</xref>). Knockdown of IRF9 in Ren-02 cells also significantly boosted tumor growth in a xenograft model (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>), IRF9 suppression did not reduce the expression of other subunits of ISGF3 (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>), and IRF9 suppression was maintained in the endpoint tumors (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2B</xref>). Furthermore, we stably suppressed the expression of either STAT1 or STAT2 in 786-O cells then performed xenograft analysis. In both cases, the tumors were significantly bigger than the ones made by the control cells (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>). These data strongly suggest that ISGF3 has potent anti-tumor activity <italic>in vivo</italic>.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Suppression of IRF9, a key component of ISGF3, led to enhanced tumor growth and significantly less tumor-infiltrating immune cells.</title><p>(<bold>A</bold>) SDS-solubilized whole cell lysates of 786-O cells expressing control shRNA or shRNA against IRF9 were blotted with indicated antibodies; (<bold>B</bold>) The growth rate of the indicated cell lines measured by WST-1 assay; (<sc><bold>C</bold></sc>) Pictures of mice and xenografted tumors and (<bold>D</bold>) Quantification of tumor weights originating from same number of cancer cells described in (<bold>A</bold>) in athymic nude mice. The p-value was calculated with two-tailed student t test; (<bold>E</bold>) H&amp;E or immunohistochemistry stains of slides from the representative pair five tumors. The percentages of CD45- or Ki67-positive cancer cells in the tumors were quantified with analytic programs in Aperio software. The p-values were calculated with Mann Whitney-Wilcoxon.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig7-v3.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Suppression of IRF9 significantly enhanced tumor growth by Ren-02 cells.</title><p>VHL-deficient ccRCC cells Ren-02 were stably infected with SCR or IRF9-sh69. (<bold>A</bold>) Pictures of mice and xenografted tumors and (<bold>B</bold>) Quantification of tumor weights originating from same number of cancer cells in athymic nude mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig7-figsupp1-v3.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Stable suppression of IRF9 in ccRCC cells and xenograft tumors.</title><p>(<bold>A</bold>) The IRF9 was suppressed by shRNA in 786-O or Ren-02 cells. The lysates were examined with indicated antibodies. (<bold>B</bold>) Lysates were made from two pairs of tumors described in <xref ref-type="fig" rid="fig7">Figure 7C</xref> (derived from 786-O cells) and immunoblotted with indicated antibodies.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig7-figsupp2-v3.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Suppression of STAT1 or STAT2 promotes tumor growth.</title><p>STAT1 (<bold>A</bold>) and STA2 (<bold>B</bold>) were stably suppressed by shRNA in 786-O cells. Control cells and STAT1 or STAT2-suppressed cells were subjected to xenograft analysis. (<bold>C</bold>) and (<bold>E</bold>) Pictures of mice and xenografted tumors. (<bold>D</bold>) and (<bold>F</bold>) Quantification of tumor weights originating from the same number of cancer cells in nude mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig7-figsupp3-v3.tif"/></fig><fig id="fig7s4" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 4.</label><caption><title>IRF9 loss does not lead to significant changes in apoptosis or blood vessel density.</title><p>Representative 786-O xenograft tumors expressing SCR or IRF9-sh69 were subjected to H&amp;E or immunohistochemistry analyses with indicated antibodies.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig7-figsupp4-v3.tif"/></fig></fig-group><p>In order to learn the reason for enhanced tumor growth after IRF9 knockdown, we performed hematoxylin and eosin(H&amp;E) and immunohistochemistry (IHC) staining on five pairs of 786-O SCR and IRF9-69 tumors. The control tumors contained higher percentages of mouse stromal cells, while the IRF9 knockdown tumors were mostly comprised of cancer cells (<xref ref-type="fig" rid="fig7">Figure 7E</xref> and <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>). The cancer cells in tumors with IRF9 knockdown had a slight but insignificant increase in Ki67 staining, a marker for cell proliferation, over cancer cells in control tumors (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). However, CD45 staining, a marker for all mouse immune cells, was significantly higher in control tumors compared to IRF9 knockdown tumors (<xref ref-type="fig" rid="fig7">Figure 7E</xref>, p=0.007). There were no significant differences in cleaved caspase three or CD31, markers for apoptosis or blood vessels, respectively (<xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>). Thus the lack of infiltrating host immune cells into the tumors formed by ccRCC cells depleted of IRF9, not changes in cell proliferation, apoptosis, or blood vessel growth, might be the primary reason of enhanced growth.</p></sec><sec id="s2-8"><title>Over-expression of ISGF3 in PBRM1-deficient ccRCC cells strongly suppresses tumor growth</title><p>Suppression of IRF9 in 786-O or Ren-02 cells greatly enhanced tumor growth (<xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). As PBRM1 suppression led to reduced ISGF3 expression and activity (<xref ref-type="fig" rid="fig5">Figure 5</xref>) and enhanced tumor growth (data not shown), we asked whether ISGF3 over-expression reverses the enhanced tumor growth elicited by PBRM1 deficiency. To this end, we stably infected 786-O PBRM1-sh94 cells with different combinations of viral vectors expressing STAT1, STAT2 or IRF9. The combination of STAT2 +IRF9 or all three factors strongly induced ISGF3 targets PLSCR1 and MX1 (<xref ref-type="fig" rid="fig8">Figure 8A</xref>) and we chose the cells expressing STAT2 +IRF9 for further analysis. The over-expression of STAT2 +IRF9 did not change cell growth in culture (<xref ref-type="fig" rid="fig8">Figure 8B</xref>), however, overexpression of these ISGF3 components strongly suppressed tumor growth by PBRM1-deficient 786-O cells in a xenograft model (<xref ref-type="fig" rid="fig8">Figure 8C and D</xref>).Thus depletion of ISGF3 greatly enhanced tumor growth while its activation very potently blocked it, suggesting that ISGF3 is a central player in ccRCC tumor growth that is targeted by most of the cancer genes.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Over-expression of IRF9 and STAT2 restored ISGF3 function and retarded tumor growth of 786-O cells with PBRM1 suppressed.</title><p>(<bold>A</bold>) 786-O cells were infected with the indicated viral vectors. SDS-solubilized whole cell lysates were blotted with the indicated antibodies. (<bold>B</bold>) Cellular growth of indicated cell lines measured by WST-1 assay; (<bold>C</bold>) Pictures of mice and xenografted tumors and (<bold>D</bold>) Quantification of tumor weights originating from the same number of cancer cells expressing either an empty vector or STAT2 plus IRF9 in athymic nude mice. The p-value was calculated with two-tailed student t test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig8-v3.tif"/></fig></sec><sec id="s2-9"><title>IRF9 and STAT2 expression significantly correlated with the expression of PBRM1, SETD2, or BAP1 in human ccRCC tumors</title><p>To verify that the observations are relevant for human ccRCC, we analyzed TCGA ccRCC datasets to investigate possible connection between ISGF3 and the secondary tumor suppressors. However, we did not find consistent correlations between mRNA levels of BAP1, PBRM1, KDM5C, SETD2 and ISGF3 components in the whole tumors (data not shown). One possibility for these results is that the mRNA expression of ISGF3 components detected in TCGA is not primarily coming from cancer cells, but from other stromal cells which can distort the results. To investigate this, we analyzed the correlations between well-known immune and tumor cell markers (CD45 or PTPRC, CD3, CD8, etc and CDH1, EPCAM) with ISGF3 subunits within the TCGA dataset. We found that the mRNA expression of ISGF3 subunits in the TCGA dataset comes predominantly from immune cells as opposed to tumor cells (surrogated by EPCAM and E cadherin) (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>). We also sought to confirm this with immunohistochemistry (IHC). We found that immune cells had much higher protein expression of ISGF3 subunits STAT2 than the normal or cancerous human kidney cells. On the same slide, the immune cells in lymph node, spleen and lung tissues were stained strongly positive with antibody against STAT2, but the normal and cancerous kidney tissue stained negative or very weakly (<xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2A</xref>). Interestingly, in the lung tissue, the strong staining of STAT2 in the immune cells did not seem to significantly increase the staining intensity of the surrounding cells. Similar observation was made with IRF9 IHC (<xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2B</xref>). Thus immune cells have much higher expression of ISGF3 subunits STAT2 and IRF9 than that in kidney cancer cells, and this could disrupt the detection of ISGF3 mRNA expression in the cancer cells. Since our hypothesis is that BAP1, PBRM1, KDM5C, SETD2 are critical to maintain the expression and/or function of ISGF3 subunits in the ccRCC cancer cells, we concluded that mRNA levels in the bulk tumors from the TCGA dataset are not suitable for our validation experiments.</p><p>To validate our hypothesis, we decided to examine the ISGF3 protein levels in ccRCC cancer cells with IHC and correlate their protein levels with the protein levels of BAP1, PBRM1, and SETD2. We have previously examined the protein levels of PBRM1 and SETD2 in a ccRCC tissue microarray (TMA) generated by our colleagues at Fox Chase Cancer Center in our previous publication (<xref ref-type="bibr" rid="bib30">Jiang et al., 2016</xref>). The specificity of the BAP1 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), STAT2 (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3</xref>) and IRF9 (<xref ref-type="fig" rid="fig9s3">Figure 9—figure supplement 3A</xref>) antibodies used for IHC was validated by western blots. We probed the same TMA with antibodies against BAP1, IRF9 and STAT2. The staining of BAP1 or IRF9 mostly occurs in the nucleus, while STAT2 staining is found in both cytoplasm and nucleus (<xref ref-type="fig" rid="fig9s3">Figure 9—figure supplement 3B</xref>). In many cases the protein expression levels of PBRM1, SETD2 or BAP1 correlated with that of STAT2 or IRF9 on the same tumor samples (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). After scoring the samples and performing statistical analysis, the Spearman association analysis revealed that nuclear IRF9 and cytoplasmic STAT2 both significantly correlated with the expression of PBRM1, SETD2, or BAP1 (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). The correlations were mostly statistically significant when all foci were considered and in individual tumor stage or grade. Interestingly, the loss of nuclear staining of IRF9 was associated with worse patient survival, consistent with a tumor suppressor role of ISGF3 (<xref ref-type="fig" rid="fig9">Figure 9C</xref>). The loss of cytoplasmic STAT2 staining was not associated with worse patient survival (<xref ref-type="fig" rid="fig9">Figure 9D</xref>), suggesting that other ISGF3 components are the more dominant players in the human ccRCC. Consistent with this idea, the change of IRF9 protein in the TMA (<xref ref-type="fig" rid="fig9">Figure 9B</xref>) and in the cultured cells (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>) tracked better with the changes of PBRM1, SETD2 or BAP1. Taken together, our data suggest that the links between PBRM1, SETD2 or BAP1 and ISGF3 are preserved in human ccRCC tumors.</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>IRF9 and STAT2 expression significantly correlated with the expression of PBRM1, SETD2, or BAP1 in ccRCC tumors.</title><p>(<bold>A</bold>) 20x IHC images of representative ccRCC foci stained with indicated antibodies. (<bold>B</bold>) Spearman correlation coefficient, rho, and p-value of nuclear (nuc) IRF9 or cytoplasmic (cyto) IHC signals with those of PBRM1, SETD2 or BAP1. The analysis was performed with either all the foci or the foci within each tumor stage or tumor grade. (<bold>C</bold>) Kaplan-Meier curves of patient overall survival based on the positive or negative IHC signal of nuclear IRF9 and (<bold>D</bold>) cytoplasmic STAT2. Statistical significance calculated using the log-rank test. (<bold>E</bold>) A schematic diagram showing how HIF and secondary tumor suppressors converge on ISGF3 to regulate tumor growth in ccRCC. HIF activates ISGF3 that suppresses tumor growth. PBRM1, KDM5C, SETD2 and BAP1 all support the function of ISGF3. Mutations in any of them relieve the tumor suppressive function of HIF2α.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig9-v3.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>ISGF3 subunits correlate positively with immune cell markers and negatively with cancer cell markers in the TCGA dataset.</title><p>Correlations between IRF9, STAT1 or STAT2 with immune and tumor cell markers within the TCGA dataset. N = 534; PTPRC, CD45; CD247, T-Cell Receptor T3 Zeta Chain; CD3G, T-Cell Receptor T3 Gamma Chain; CDH1, E-cadherin.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig9-figsupp1-v3.tif"/></fig><fig id="fig9s2" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 2.</label><caption><title>STAT2 and IRF9 protein levels are significantly higher in immune cells than that in kidney cells.</title><p>IHC images of STAT2 (<bold>A</bold>) and IRF9 (<bold>B</bold>) stained human tissue samples from kidney, renal cell carcinoma, lymph node, spleen, and lung. For each antibody, the top is the macroscopic image of the slide, and the bottom shows the 20x image of each tissue.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig9-figsupp2-v3.tif"/></fig><fig id="fig9s3" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 3.</label><caption><title>IHC staining of ccRCC tumors with BAP1, IRF9 or STAT2 antibodies.</title><p>(<bold>A</bold>) 786-O cells were infected with the indicated shRNA constructs and the lysates were immunoblotted with indicated antibodies. (<bold>B</bold>) Representative images of foci from the TMA that were stained with indicated antibodies. Scoring: 2:&gt;=50% of cancer cells stained positive; 1: 5–49% of cancer cells stained positive; 0:&lt;5% of cancer cells stained positive.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-fig9-figsupp3-v3.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Although the overall activity of HIF is strongly oncogenic, our previous results indicate that it also triggers a significant anti-tumor response. For instance, KDM5C is induced by HIF, and its demethylase activity against global H4K4me3 mark is dependent on HIF in <italic>VHL-/-</italic>ccRCC cells, and yet it clearly plays an anti-tumor role in ccRCC (<xref ref-type="bibr" rid="bib45">Niu et al., 2012</xref>). In addition, some other HIF downstream targets, such as VEGF or Cyclin D1, are strongly pro-tumor growth, whereas other HIF downstream targets such as GLUT1 or IGFBP3, are obviously tumor suppressive (<xref ref-type="bibr" rid="bib75">Zhang et al., 2013</xref>). Consistent with this, <italic>Vhl</italic> conditional knockout in mouse kidneys alone is not sufficient to generate ccRCC despite fully activated HIF. Only after combination with <italic>Pbrm1</italic> or <italic>Bap1</italic> conditional knockout can <italic>Vhl</italic> loss lead to kidney tumors (<xref ref-type="bibr" rid="bib43">Nargund et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Gu et al., 2017</xref>). Thus HIF could activate ISGF3, which constitutes a negative feedback loop in ccRCC. Its inhibitory effect on tumor growth can be relieved by the loss of PBRM1, KDM5C, SETD2 or BAP1 to promote robust tumor growth (<xref ref-type="fig" rid="fig9">Figure 9E</xref>).</p><p>ISGF3 is traditionally activated by interferon stimulation through phosphorylation of STAT1 and STAT2 (<xref ref-type="bibr" rid="bib8">Borden et al., 2007</xref>). However, days after the initial activation, the posttranslational modifications (PTMs) disappear, yet ISGF3 can still maintain its activity as unphosphorylated ISGF3 (U-ISGF3) with greatly enhanced protein levels (<xref ref-type="bibr" rid="bib13">Cheon et al., 2013</xref>). U-ISGF3 activates fewer targets than phosphorylated ISGF3, but it still potently antagonizes viral infection and DNA damage. In oncology, ISGF3 is known to be a predictive biomarker for chemotherapy and radiation in breast cancer (<xref ref-type="bibr" rid="bib67">Weichselbaum et al., 2008</xref>), and it is also associated with drug-resistance to immune checkpoint blockade (<xref ref-type="bibr" rid="bib5">Benci et al., 2016</xref>). Recently, immune checkpoint inhibitors, specifically those that target Programmed Death 1 (PD-1), Programmed Death Ligand 1 (PD-L1), and Cytotoxic T-Lymphocyte Associated 4 (CTLA-4) have gained traction in metastatic RCC (mRCC). The FDA has granted priority review for ipilimumab/nivolumab in intermediate and poor-risk mRCC (<xref ref-type="bibr" rid="bib2">Abernathy, 2017</xref>), with RCC experts declaring this combination the new standard of care in the treatment of mRCC (<xref ref-type="bibr" rid="bib15">Chustecka, 2017</xref>; <xref ref-type="bibr" rid="bib52">Rini, 2017</xref>). Loss-of-function mutations in <italic>PBRM1</italic> were discovered to confer clinical benefit to ccRCC patients treated with anti-PD-1 alone or in combination with anti-CTLA-4 therapies (<xref ref-type="bibr" rid="bib42">Miao et al., 2018</xref>). In addition, <italic>PBRM1</italic> mutations were found to enhance T-cell-mediated killing in an unbiased, high-throughput screen in a melanoma model (<xref ref-type="bibr" rid="bib46">Pan et al., 2018</xref>). As <italic>PBRM1</italic> and other ccRCC tumor suppressor genes (TSGs) converge on ISGF3, it will be very interesting to examine whether ISGF3 status is a predictive biomarker for response to immunotherapy. The fact that <italic>PBRM1</italic> mutations, but not those of <italic>BAP1</italic>, <italic>SETD2</italic>, and <italic>KDM5C</italic>, are a predictive biomarker for response to immunotherapy is likely because <italic>PBRM1</italic> and <italic>BAP1</italic> mutations are truncal (root change) in many cases while the mutations of the other two are subclonal (<xref ref-type="bibr" rid="bib20">Gerlinger et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Gerlinger et al., 2014</xref>). <italic>BAP1</italic> mutations might also elicit an additional change that cancels their immunotherapy-sensitizing effect.</p><p>ccRCC is known to harbor rampant intra-tumoral heterogeneity (<xref ref-type="bibr" rid="bib20">Gerlinger et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Gerlinger et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Jiang et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Jiang et al., 2017</xref>). Inactivating mutations in <italic>PBRM1</italic>, <italic>SETD2</italic>, <italic>KDM5C</italic> and <italic>BAP1</italic> tend to be focal in the tumors, so therapies that are designed to exploit the weakness induced by mutation of an individual gene could be problematic since it cannot treat the remaining cancer cells free of that mutation. Since the suppression of PBRM1, KDM5C, SETD2 or BAP1 all lead to the reduction of ISGF3, a potent tumor suppressor, it is possible that any effective therapeutic intervention that restores ISGF3 function could benefit ccRCC patients with a wide variety of mutations.</p><p><italic>Pbrm1</italic> loss in mice and <italic>PBRM1</italic>-/- vs PBRM1 re-expressed human A704 cells showed that PBRM1 deficiency was linked to the activation of the JAK/STAT3 pathway (<xref ref-type="bibr" rid="bib43">Nargund et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Miao et al., 2018</xref>). STAT3 and ISGF3 are two different, often times opposing, pathways: ISGF3 is activated by type I IFN (<xref ref-type="bibr" rid="bib13">Cheon et al., 2013</xref>), while STAT3 is activated by the IL6 family, oncogenes, and growth factors (<xref ref-type="bibr" rid="bib26">Heinrich et al., 1998</xref>). They have very different gene targets. STAT3 is often considered an oncogene (<xref ref-type="bibr" rid="bib72">Yuan et al., 2016</xref>), while STAT1 is usually considered a TSG (<xref ref-type="bibr" rid="bib59">Stephanou and Latchman, 2003</xref>), and thus they appear to play opposing biological roles in tumorigenesis (<xref ref-type="bibr" rid="bib3">Avalle et al., 2012</xref>). In human T lymphoma cells or mouse cells, loss of STAT3 leads to prolonged activation of STAT1 (<xref ref-type="bibr" rid="bib51">Regis et al., 2008</xref>; <xref ref-type="bibr" rid="bib16">Costa-Pereira et al., 2002</xref>; <xref ref-type="bibr" rid="bib41">Maritano et al., 2004</xref>). In addition, STAT3 negatively regulates the type I IFN signaling pathway by inhibiting expression of <italic>IRF7</italic>, <italic>IRF9</italic>, <italic>STAT1 </italic>in diffuse large B cell lymphoma (<xref ref-type="bibr" rid="bib40">Lu et al., 2018</xref>). Thus STAT3 and ISGF3 are distinct and activated STAT3 might suppress ISGF3 in ccRCC cells, and this deserves further investigation.</p><p>In a recent publication, SETD2 was shown to methylate STAT1 to promote ISGF3 function (<xref ref-type="bibr" rid="bib12">Chen et al., 2017</xref>). However, this requirement of SETD2 is not observed unless IFN is added to activate ISGF3. In our system, no exogenous IFN was present, and HIF activation seemed to be sufficient to increase the protein levels of STAT2 and IRF9, thus it might activate U-ISGF3 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). In 786-O cells with or without PBRM1 or KDM5C suppression, the mRNA levels of STAT1, STAT2 and IRF9 mirror that of the proteins (data not shown), suggesting that the regulation of U-ISFG3 occurred at the transcriptional level. Interestingly, BAP1 loss reduced the protein levels of STAT2 and IRF9 independent of PBRM1 status, since RCC4 cells express no endogenous PBRM1 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>).</p><p>Why ISGF3 is a potent tumor suppressor in ccRCC tumors is currently not well understood. One possibility is that interferon stimulated genes (ISG) have anti-proliferative and pro-apoptotic function in ccRCC cancer cells. ISGs activated by IFN do have such activity to curb the spread of virus in the infected cells (<xref ref-type="bibr" rid="bib8">Borden et al., 2007</xref>), and the U-ISGF3 was thought to be weaker in this regard with a much smaller target pool (<xref ref-type="bibr" rid="bib13">Cheon et al., 2013</xref>). However, the U-ISGF3 may still possess sufficient anti-proliferative/pro-apoptotic activity to impair the fitness of the cancer cells. Our current evidence suggests that this does not apply in our model. Alternatively, U-ISGF3 may change how the cancer cells interact with the immune system. The nude mice used in our study do not have adaptive immune system but the innate immune response remains intact. The heightened U-ISGF3 may attract more innate immune cells such as macrophages and NK cells to attack the tumors and curb tumor growth, as a previous report showed that over-expression of IFN-β recruited macrophages which suppressed tumor growth and metastasis in nude mice (<xref ref-type="bibr" rid="bib73">Zhang et al., 2002</xref>). However, further studies to closely monitor the cancer and host cells are needed to provide a definitive answer to this question. It will be important to identify the mechanism of how ISGF3 curbs tumor growth in ccRCC with human tumor samples and immune-competent mouse models so we can exploit this pathway to treat ccRCC patients.</p><p>With our current preliminary data we think that PBRM1 and KDM5C regulate ISGF3 subunits at transcriptional level, while SETD2 and BAP1 regulate ISGF3 at post-translational modification level. They might use quite different mechanisms to achieve the same goal: maintaining the ISGF3 activity, so loss of any of them could promote tumor development. Further investigation into these mechanisms is needed.</p><p>It is highly surprising that so many major TSGs in ccRCC share the same target in ISGF3. Undoubtedly each TSG has its own unique tumor suppressing functions, as each carries different prognoses for the patients. <italic>KDM5C</italic> mutations were reported to occur in the cells with <italic>PBRM1</italic> mutations (<xref ref-type="bibr" rid="bib27">Hsieh et al., 2017</xref>). It is possible that their unique tumor suppressor functions are synergistic so their mutations are selected in the same cells during tumor development. However, the fact that they all converge on ISGF3 warrants further investigation into how this pathway impacts drug response, patient survival, animal modeling and drug development.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th colspan="2">Source or reference</th><th colspan="2">Identifiers</th><th>Additional information</th></tr></thead><tbody><tr valign="top"><td>Cell line (Human)</td><td>786-O</td><td colspan="2">purchased from ATCC</td><td colspan="2">ATCC CRL-1932</td><td/></tr><tr valign="top"><td>Cell line (Human)</td><td>A498</td><td colspan="2">purchased from ATCC</td><td colspan="2">ATCC CRL-7908</td><td/></tr><tr valign="top"><td>Cell line (Human)</td><td>Ren-01</td><td colspan="2">Daniel Lindner <break/>at Cleveland Clinic</td><td colspan="2"/><td/></tr><tr valign="top"><td>Cell line (Human)</td><td>Ren-02</td><td colspan="2">Daniel Lindner <break/>at Cleveland Clinic</td><td colspan="2"/><td/></tr><tr valign="top"><td>Cell line (Human)</td><td>RCC4</td><td colspan="2">William Kaelin Jr. <break/>at Dana-Farber <break/>Cancer Institute</td><td colspan="2"/><td/></tr><tr valign="top"><td>Cell line (Human)</td><td>Caki-1</td><td colspan="2">William Kaelin Jr. <break/>at Dana-Farber <break/>Cancer Institute</td><td colspan="2"/><td/></tr><tr valign="top"><td>Cell line (Human)</td><td>HEK293T</td><td colspan="2">William Kaelin Jr. <break/>at Dana-Farber <break/>Cancer Institute</td><td colspan="2"/><td/></tr><tr valign="top"><td>Cell line (Human)</td><td>UMRC2</td><td colspan="2">Qing Zhang at UNC <break/>Chapel Hill</td><td colspan="2"/><td/></tr><tr valign="top"><td>Cell line (Human)</td><td>UMRC6</td><td colspan="2">Qing Zhang at UNC <break/>Chapel Hill</td><td colspan="2"/><td/></tr><tr valign="top"><td>Antibody</td><td>BAP1 (mouse monoclonal)</td><td colspan="2">Santa Cruz Biotech, <break/>sc-28383</td><td colspan="2"/><td> (1:200 for western blot, <break/>1:50 for IHC)</td></tr><tr valign="top"><td>Antibody</td><td>STAT2 (rabbit polyclonal)</td><td colspan="2">Bethyl A303-512A</td><td colspan="2"/><td>(1:1,000 for western blot, <break/>1:25 for IHC)</td></tr><tr valign="top"><td>Antibody</td><td>IRF9 (rabbit polyclonal)</td><td colspan="2">Sigma, HPA001862</td><td colspan="2"/><td>(1:2,000 for western blot, <break/>1:50 for IHC)</td></tr><tr valign="top"><td>Recombinant DNA reagent</td><td>Flag-PBRM1 (human)</td><td colspan="2">This paper</td><td colspan="2"/><td>Available upon request.</td></tr><tr valign="top"><td>Recombinant DNA reagent</td><td>Flag-KDM5C (human)</td><td colspan="2">This paper</td><td colspan="2"/><td>Available upon request.</td></tr><tr valign="top"><td>Other</td><td>Ren-02 cells with BAP1 knocked out</td><td colspan="2">This paper</td><td colspan="2"/><td>BAP1 gene was knocked <break/>out with the CrRISPR-Cas9 <break/>technique. Detailed description <break/>was listed in the Materials <break/>and methods.</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Gene expression analysis</title><p>Genome-wide gene transcription was profiled using Illumina HumanHT-12_V4 Expression Bead Chip. The raw gene expression data were preprocessed in Genome Studio (<ext-link ext-link-type="uri" xlink:href="https://www.illumina.com/techniques/microarrays/array-data-analysis-experimental-design/genomestudio.html">https://www.illumina.com/techniques/microarrays/array-data-analysis-experimental-design/genomestudio.html</ext-link>), and further processed using R limma package (<xref ref-type="bibr" rid="bib53">Ritchie et al., 2015</xref>) for force-positive background correction, log<sub>2</sub> transformation and quantile normalization. Data quality control was performed by selecting present probes using the detection threshold of 0.05. Outlier samples were examined using hierarchical clustering and no samples were removed. The average value across the probesets of an annotated gene was used as the gene-level expression and the data matrix was exported for downstream analysis. Differential gene expression analyses were performed using limma package controlling for batch effects in a linear model (<xref ref-type="bibr" rid="bib49">Phipson et al., 2016</xref>). Gene set enrichment was performed using a preranked GSEA algorithm (<xref ref-type="bibr" rid="bib60">Subramanian et al., 2005</xref>) based on log<sub>2</sub> fold change. GO analyses were performed using the DAVID (<xref ref-type="bibr" rid="bib28">Huang et al., 2009</xref>) online tools. For the GO analyses, Venn diagrams, and heatmaps, the cutoff of adjusted p-value less than 0.05 and fold change greater than two were applied to select genes. The statistical significance of the overlaps in the Venn diagrams was calculated based on hypergeometric distribution function – <italic>phyper</italic> implemented in R (<ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link>). The gene expression values used in the heatmaps were preprocessed by ComBat (<xref ref-type="bibr" rid="bib32">Johnson et al., 2007</xref>) to remove batch effects, and then centered by the mean values of each row. Source file: GEO accession GSE108229.</p></sec><sec id="s4-2"><title>Analysis of TCGA dataset</title><p>Gene expression for the TCGA dataset, Kidney renal cell carcinoma (KIRC), were obtained through the ‘cgdsr’ R package (<xref ref-type="bibr" rid="bib29">Jacobsen and cBioPortal Questions, 2018</xref>). RSEM expression data were transformed into log2(RSEM +1). Transformed data were used for Pearson correlation and plotted with the ‘ggplot2’ R package (<xref ref-type="bibr" rid="bib68">Wickham, 2016</xref>). Scripts available upon request.</p></sec><sec id="s4-3"><title>Analysis of TMA</title><p>Association between different IHC targets were determined using Spearman correlation. Kaplan-Meier survival analyses were performed and plotted using ‘survival’ and ‘survminer’ R packages (<xref ref-type="bibr" rid="bib36">Kassambara et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Therneau and Lumley, 2015</xref>; <xref ref-type="bibr" rid="bib62">Therneau and Patricia, 2000</xref>). Statistical significance of survival curves was calculated using the log-rank test.</p></sec><sec id="s4-4"><title>Mutagenesis, subcloning and primers for RT-PCR</title><p>Mutagenesis was performed via the QuikChange method using phusion DNA polymerase (ThermoFisher). Primers were designed using Agilent’s QuikChange Primer Design program. The sequences are as follows: BAP1-N78S-F: CTGGTGGGCAAAGAACATGTTACTCACAATATCATCATCAATCAC, BAP1-N78S-R: GTGATTGATGATGATATTGTGAGTAACATGTTCTTTGCCCACCAG, BAP1-G185R-F: GACCTTCAGCCTATCCAGCTCAAAGAGCCG, BAP1-G185R-R: CGGCTCTTTGAGCTGGATAGGCTGAAGGTC. A temperature gradient was performed to ensure primer annealing during PCR cycling. Following DpnI digestion, DNA was transformed into XL10 Gold Ultracompetent Cells (Agilent). Plasmids were sequenced to confirm the point mutations.</p><p>Full-length PBRM1 was subcloned into p3xFlag-CMV10 with primers PBRM1-F: CCCAAGCTTATGGGTTCCAAGAGAAGAAG and PBRM1-R: GGAATTCTTAAACATTTTCTAGGTTGT. For 1–1297 and 1–1184 PBRM1 constructs, the following primers were used to introduce nonsense mutants through mutagenesis:</p><p>1297 (3892C-T): 3892 F: CCAATTGTTCCTTAGAAGGAGCCAT; 3892 R: ATGGCTCCTTCTAAGGAACAATTGG</p><p>1184 (3553C-T): 3553 F: AAAGTATGGGTTTGAGATGGAGCTG; 3553 R: CAGCTCCATCTCAAACCCATACTTT</p><sec id="s4-4-1"><title>Primers for real-time PCR</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Primer name</th><th valign="top">Primer sequence</th></tr></thead><tbody><tr><td valign="top">GAPDH-F</td><td valign="top">TGCACCACCAACTGCTTAGC</td></tr><tr><td valign="top">GAPDH-R</td><td valign="top">GGCATGGACTGTGGTCATGAG</td></tr><tr><td valign="top">OAS1-F</td><td valign="top">CATCTGTGGGTTCCTGAAGG</td></tr><tr><td valign="top">OAS1-R</td><td valign="top">GAGAGGACTGAGGAAGACAAC</td></tr><tr><td valign="top">OAS2-F</td><td valign="top">CAGTCCTGGTGAGTTTGCAGT</td></tr><tr><td valign="top">OAS2-R</td><td valign="top">ACAGCGAGGGTAAATCCTTGA</td></tr><tr><td valign="top">IFI44-L</td><td valign="top">TTCGATGCGAAGATTCACTG</td></tr><tr><td valign="top">IFI44-R</td><td valign="top">CCCTTGGAAAACAGACCTCA</td></tr><tr><td valign="top">IFI44L-F</td><td valign="top">GAGCACAGAAATAGGCTTCTAGC</td></tr><tr><td valign="top">IFI44L-R</td><td valign="top">TGGTATCAGACCCCACTACGG</td></tr><tr><td valign="top">IFIT1-F</td><td valign="top">CTGAATGCAGCTCACCTCTG</td></tr><tr><td valign="top">IFIT1-R</td><td valign="top">GGATGGAATTGCCTGCTAGA</td></tr><tr><td valign="top">ISG20-F</td><td valign="top">GTCACCCCTCAGCACATG</td></tr><tr><td valign="top">ISG20-R</td><td valign="top">AGATTGTGTAGCCGCTCATG</td></tr><tr><td valign="top">GAS6-F</td><td valign="top">AGACTATCACTCCACGAAG</td></tr><tr><td valign="top">GAS6-R</td><td valign="top">TCGCAGACCTTGATCTCC</td></tr><tr><td valign="top">STMN3-F</td><td valign="top">CAGCACCATTTCCGCCTA</td></tr><tr><td valign="top">STMN3-R</td><td valign="top">CCTCCATGTCCCCGTA</td></tr><tr><td valign="top">ARPC4-F</td><td valign="top">TCAGTCAATGCCCGTG</td></tr><tr><td valign="top">ARPC4-R</td><td valign="top">CTCCAGGACGCCTTCG</td></tr><tr><td valign="top">IL6-F</td><td valign="top">CCAGCTATGAACTCCTTCTC</td></tr><tr><td valign="top">IL6-R</td><td valign="top">GCTTGTTCCTCACATCTCTC</td></tr><tr><td valign="top">IL8-F</td><td valign="top">ATCGCTTCCTCTCGCAACAA</td></tr><tr><td valign="top">IL8-R</td><td valign="top">CTTCTACTGGTTCAGCAGCCATCT</td></tr><tr><td valign="top">CCL5-F</td><td valign="top">TCTGCGCTCCTGCATCTG</td></tr><tr><td valign="top">CCL5-R</td><td valign="top">GGGCAATGTAGGCAAAGCA</td></tr><tr><td valign="top">SETD2-F:</td><td valign="top">ATCGAGAGAGGACGCGCTATT</td></tr><tr><td valign="top">SETD2-R:</td><td valign="top">AGGTACGCCTTGAGTATGTCTT</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4-5"><title>Cell culture and viral infection</title><p>Kidney cancer cell lines 786-O and A498 were purchased from ATCC. Ren-02, RCC4 and HEK293T were described previously (<xref ref-type="bibr" rid="bib45">Niu et al., 2012</xref>; <xref ref-type="bibr" rid="bib44">Negrotto et al., 2011</xref>). UMRC2 and UMRC6 cells were a gift from Dr. Qing Zhang from University of North Carolina at Chapel Hill. All cell lines were maintained in 37°C incubator with 5% CO<sub>2</sub> in glutamine-containing DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin. Mycoplasma contamination is tested with a PCR-based kit. The cells will be treated with antibiotics to eradicate the mycoplasma if it is detected. The cell proliferation rate was measured with a WST-1 kit from Sigma Aldrich according to the manufacturer’s instruction.</p><p>The packaging of shRNA viral particles, the infection and selection, and the expression of shRNA resistant plasmid were the same as described before (<xref ref-type="bibr" rid="bib37">Kondo et al., 2002</xref>).</p></sec><sec id="s4-6"><title>The generation of Ren-02 BAP1 knockout (KO) clone</title><p>Ren-02 BAP1 knockout (KO) cells were generated using an inducible CRISPR-Cas9 system previously described (<xref ref-type="bibr" rid="bib11">Cao et al., 2016</xref>). Briefly, HEK293T cells were transfected with 2 μg pLenti-iCas9-Neo, 2μgΔR8.9 packaging vector, and 200 ng VSV-G envelope vector using lipofectamine 2000. Lentiviral supernatants were filtered and used to infect Ren-02 cells with polybrene, and infected cells were selected with 1.0 mg/ml G418. The cells were then treated with 1.0 μg/ml doxycycline to induce Cas9 expression, and sorted by GFP expression using flow cytometry. Short guide RNA (sgRNA) sequences were designed to target BAP1 exon five using Optimized Crispr Design (crispr.mit.edu), using the following oligonucleotides: BAP1-exon5-F: CACCGACCCACCCTGAGTCGCATGA; BAP1-exon5-R: AAACTCATGCGACTCAGGGTGGGTC. The sgRNAs were cloned into pLentiGuide-Puro as previously described (<xref ref-type="bibr" rid="bib54">Sanjana et al., 2014</xref>; <xref ref-type="bibr" rid="bib57">Shalem et al., 2014</xref>). The pLentiGuide-Puro-sgRNA plasmids were transfected into HEK293T cells to generate lentivirus, which was used to infect Ren-02 iCas9 cells. Following selection with 2.0 μg/ml puromycin, the Ren-02 iCas9-sgRNA cells were treated with doxycycline, diluted, and screened to identify individual clones with BAP1 KO.</p></sec><sec id="s4-7"><title>Western blot and immunoprecipitation</title><p>Cells were washed in PBS buffer, then lysed with EBC buffer (50 mM Tris, pH 8.0; 120 mM NaCl; 0.5% NP-40) supplemented with a protease inhibitor cocktail. In some cases 1% SDS solution was added to the cells in the plates instead of EBC buffer, then the solution was sonicated at 20 A for 3 × 15 s pulses and mixed with sample buffer. The same total amount of total protein was loaded and resolved by SDS–PAGE and analyzed by immunoblotting. The blots were developed with Super Signal Pico substrate (Pierce Biotechnology, Rockford, IL) or Immobilon Western substrate (Millipore, Billerica, MA). Immunoprecipitations were performed with EBC lysates as previously described (<xref ref-type="bibr" rid="bib45">Niu et al., 2012</xref>).</p><p>The antibodies used in this manuscript are: HA (Covance MMS-101P-1000 HA.11 (16B12 for IB, Santa Cruz Biotech sc-805 for IP), Flag (Sigma F3165-1mg (M2)), KDM5C (Bethyl A301-034A and A301-035A), BAP1 (Santa Cruz Biotech sc-28383), γ-Actin (Santa Cruz Biotech sc-8432), PBRM1 (Bethyl A301-591A and A301-590A), STAT1 (Cell signaling 9172S), phospho-STAT1 (Cell signaling 9171L), STAT2 (Bethyl A303-512A-T), phospho-STAT2 (Cell signaling 88410), IRF9 (Cell signaling 76684S), MX1 (R and D AF7946), PLSCR1 (Santa Cruz Biotech sc-59645), Vinculin (Santa Cruz Biotech sc-73614), GAPDH (Santa Cruz Biotech sc-59540), HIF2α (Novus NB100-122), OAS1 (Cell signaling 14498S).</p></sec><sec id="s4-8"><title>Short hairpin RNAs (shRNAs)</title><p>All the shRNA constructs except for SCR were obtained from Sigma (St Louis, MO). The sequences were: SCR: GCGCGCUUUGUAGGAUUCGTT; HIF2a-17: CGACCTGAAGATTGAAGTGAT; HIF2a-20: CCATGAGGAGATTCGTGAGAA; PBRM1-94: CCGGAGTCTTTGATCTACAAA; PBRM1-890: CCGGAATGCCAGGCACTATA; BAP1-71: CGTCCGTGATTGATGATGATA, BAP1-74: CCACAACTACGATGAGTTCAT; SETD2-30: CCTGAAGAATGATGAGATAAT; SETD2-32: GCCCTATGACTCTCTTGGTTA; IRF9-69: GCCATACTCCACAGAATCTTA.</p></sec><sec id="s4-9"><title>Nude mice xenograft analysis</title><p>All animal experiments were conducted in accordance with protocol 01462-935A approved by the IACUC of Thomas Jefferson University and protocol 2015–11286 approved by the IACUC of Yale University. The subcutaneous nude-mice xenograft assay was performed as described (<xref ref-type="bibr" rid="bib37">Kondo et al., 2002</xref>; <xref ref-type="bibr" rid="bib69">Yan et al., 2007</xref>). For each cell line, 10<sup>7</sup> cells were injected subcutaneously into the flanks of immunocompromised male nu/nu nude mice of four weeks old purchased from Taconic or Jackson Laboratory. All mice were sacrificed by CO<sub>2</sub> inhalation 8 to 10 weeks after injection of cells, and tumors were excised and weighed. Results are reported as mean ±se. of the mean. Nine to ten pairs of tumors were compared. Results were statistically evaluated with Mann–Whitney U statistic analysis.</p></sec><sec id="s4-10"><title>Immunohistochemistry staining and image analysis</title><p>4 μm paraffin slides were deparaffinized in Shandon Varistain Gemini ES Autostainer. Antigen retrieval was performed with DAKO PTLink using Citrate Buffer (pH6.0) at 98 ˚C for a total time of 20 min. Primary immunostaining was performed using antibodies against Ki67 (abcam, Cat#: ab16667, 1:200), Cleaved Caspase 3 (Cell-Signaling, cat#:9661, 1:500) and CD45 (BD Pharmingen, Cat#: 550539, 1:200), BAP1 (Santa Cruz Biotech, sc-28383, 1:50), STAT2 (Bethyl A303-512A, 1:25), IRF9 (Sigma, HPA001862, 1:50). Antibodies were incubated at room temperature for 30 min. Biotinylated anti-Rabbit or anti-Rat (Vector Laboratories, cat#: BA-1000 and BA-4001) secondary antibodies and ABC-HRP complexes (Vector Laboratories, Cat#: PK6100) were applied following the primary antibodies with 30 min incubation of each reagent at room temperature. Three TBST washes were performed between each step above. The signals were visualized using DAB substrate (DAKO, Cat#: K3468). Slides were then washed with DI water and further processed with Hematoxylin counter stain, dehydration and clearing in Shandon Varistain Gemini ES Autostainer and coverslipped with Permount Mounting Medium.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgement</title><p> We are very grateful to Dr. Robert Silverman at Cleveland Clinic for the suggestion that ISGF3 might be responsible for the shared target genes. We thank Dr. Wei Xu at University of Wisconsin for providing the p-LNCX expression vector. We also acknowledge Dr. Qing Zhang at the University of North Carolina at Chapel Hill for providing the UMRC2 and UMRC6 cell lines. Research reported in this publication utilized the Translational Pathology Shared Resource at Sidney Kimmel Cancer Center at Jefferson Health and was supported by the National Cancer Institute of the National Institutes of Health under Award Number<bold> P30CA056036</bold>. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Validation, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Visualization</p></fn><fn fn-type="con" id="con4"><p>Validation, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con6"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con8"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con10"><p>Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con12"><p>Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Resources</p></fn><fn fn-type="con" id="con14"><p>Resources</p></fn><fn fn-type="con" id="con15"><p>Resources</p></fn><fn fn-type="con" id="con16"><p>Resources</p></fn><fn fn-type="con" id="con17"><p>Resources</p></fn><fn fn-type="con" id="con18"><p>Resources, Writing—review and editing</p></fn><fn fn-type="con" id="con19"><p>Resources, Writing—review and editing</p></fn><fn fn-type="con" id="con20"><p>Data curation, Formal analysis, Supervision, Methodology, Writing—review and editing, Funding Acquisition</p></fn><fn fn-type="con" id="con21"><p>Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Methodology, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were conducted in accordance with protocol 01462-935A approved by the IACUC of Thomas Jefferson University and protocol 2015-11286 approved by the IACUC of Yale University.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-37925-transrepform-v3.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Microarray data have been deposited inn GEO under the accession code GSE108229.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Na</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Microarray analysis of gene expression after suppression of PBRM1 or KDM5C in 786-O VHL+/+ or VHL-/- cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108229">GSE108229</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Rahman</surname> <given-names>MH</given-names></name><name><surname>Pilarski</surname> <given-names>R</given-names></name><name><surname>Cebulla</surname> <given-names>CM</given-names></name><name><surname>Massengill</surname> <given-names>JB</given-names></name><name><surname>Christopher</surname> <given-names>BN</given-names></name><name><surname>Boru</surname> <given-names>G</given-names></name><name><surname>Hovland</surname> <given-names>P</given-names></name><name><surname>Davidorf</surname> <given-names>FH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Germline BAP1 mutation predisposes to Uveal Melanoma, lung adenocarcinoma, Meningioma, and other cancers</article-title><source>Journal of Medical Genetics</source><volume>48</volume><fpage>856</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2011-100156</pub-id><pub-id pub-id-type="pmid">21941004</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Abernathy</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review</article-title><ext-link ext-link-type="uri" xlink:href="https://investors.bms.com/iframes/press-releases/press-release-details/2017/US-Food-and-Drug-Administration-FDA-Accepts-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-in-Intermediate--and-Poor-Risk-Patients-with-Advanced-Renal-Cell-Carcinoma-and-Grants-Priority-Review/default.aspx">https://investors.bms.com/iframes/press-releases/press-release-details/2017/US-Food-and-Drug-Administration-FDA-Accepts-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-in-Intermediate--and-Poor-Risk-Patients-with-Advanced-Renal-Cell-Carcinoma-and-Grants-Priority-Review/default.aspx</ext-link><date-in-citation iso-8601-date="2017-12-13">December 13, 2017</date-in-citation></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avalle</surname> <given-names>L</given-names></name><name><surname>Pensa</surname> <given-names>S</given-names></name><name><surname>Regis</surname> <given-names>G</given-names></name><name><surname>Novelli</surname> <given-names>F</given-names></name><name><surname>Poli</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>STAT1 and STAT3 in tumorigenesis: a matter of balance</article-title><source>Jak-Stat</source><volume>72</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.4161/jkst.20045</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barski</surname> <given-names>A</given-names></name><name><surname>Cuddapah</surname> <given-names>S</given-names></name><name><surname>Cui</surname> <given-names>K</given-names></name><name><surname>Roh</surname> <given-names>TY</given-names></name><name><surname>Schones</surname> <given-names>DE</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Wei</surname> <given-names>G</given-names></name><name><surname>Chepelev</surname> <given-names>I</given-names></name><name><surname>Zhao</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>High-resolution profiling of histone methylations in the human genome</article-title><source>Cell</source><volume>129</volume><fpage>823</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.05.009</pub-id><pub-id pub-id-type="pmid">17512414</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benci</surname> <given-names>JL</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Qiu</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>TJ</given-names></name><name><surname>Dada</surname> <given-names>H</given-names></name><name><surname>Twyman-Saint Victor</surname> <given-names>C</given-names></name><name><surname>Cucolo</surname> <given-names>L</given-names></name><name><surname>Lee</surname> <given-names>DSM</given-names></name><name><surname>Pauken</surname> <given-names>KE</given-names></name><name><surname>Huang</surname> <given-names>AC</given-names></name><name><surname>Gangadhar</surname> <given-names>TC</given-names></name><name><surname>Amaravadi</surname> <given-names>RK</given-names></name><name><surname>Schuchter</surname> <given-names>LM</given-names></name><name><surname>Feldman</surname> <given-names>MD</given-names></name><name><surname>Ishwaran</surname> <given-names>H</given-names></name><name><surname>Vonderheide</surname> <given-names>RH</given-names></name><name><surname>Maity</surname> <given-names>A</given-names></name><name><surname>Wherry</surname> <given-names>EJ</given-names></name><name><surname>Minn</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade</article-title><source>Cell</source><volume>167</volume><fpage>1540</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.11.022</pub-id><pub-id pub-id-type="pmid">27912061</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benusiglio</surname> <given-names>PR</given-names></name><name><surname>Couvé</surname> <given-names>S</given-names></name><name><surname>Gilbert-Dussardier</surname> <given-names>B</given-names></name><name><surname>Deveaux</surname> <given-names>S</given-names></name><name><surname>Le Jeune</surname> <given-names>H</given-names></name><name><surname>Da Costa</surname> <given-names>M</given-names></name><name><surname>Fromont</surname> <given-names>G</given-names></name><name><surname>Memeteau</surname> <given-names>F</given-names></name><name><surname>Yacoub</surname> <given-names>M</given-names></name><name><surname>Coupier</surname> <given-names>I</given-names></name><name><surname>Leroux</surname> <given-names>D</given-names></name><name><surname>Méjean</surname> <given-names>A</given-names></name><name><surname>Escudier</surname> <given-names>B</given-names></name><name><surname>Giraud</surname> <given-names>S</given-names></name><name><surname>Gimenez-Roqueplo</surname> <given-names>AP</given-names></name><name><surname>Blondel</surname> <given-names>C</given-names></name><name><surname>Frouin</surname> <given-names>E</given-names></name><name><surname>Teh</surname> <given-names>BT</given-names></name><name><surname>Ferlicot</surname> <given-names>S</given-names></name><name><surname>Bressac-de Paillerets</surname> <given-names>B</given-names></name><name><surname>Richard</surname> <given-names>S</given-names></name><name><surname>Gad</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A germline mutation in <italic>PBRM1</italic> predisposes to renal cell carcinoma</article-title><source>Journal of Medical Genetics</source><volume>52</volume><fpage>426</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102912</pub-id><pub-id pub-id-type="pmid">25911086</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bononi</surname> <given-names>A</given-names></name><name><surname>Giorgi</surname> <given-names>C</given-names></name><name><surname>Patergnani</surname> <given-names>S</given-names></name><name><surname>Larson</surname> <given-names>D</given-names></name><name><surname>Verbruggen</surname> <given-names>K</given-names></name><name><surname>Tanji</surname> <given-names>M</given-names></name><name><surname>Pellegrini</surname> <given-names>L</given-names></name><name><surname>Signorato</surname> <given-names>V</given-names></name><name><surname>Olivetto</surname> <given-names>F</given-names></name><name><surname>Pastorino</surname> <given-names>S</given-names></name><name><surname>Nasu</surname> <given-names>M</given-names></name><name><surname>Napolitano</surname> <given-names>A</given-names></name><name><surname>Gaudino</surname> <given-names>G</given-names></name><name><surname>Morris</surname> <given-names>P</given-names></name><name><surname>Sakamoto</surname> <given-names>G</given-names></name><name><surname>Ferris</surname> <given-names>LK</given-names></name><name><surname>Danese</surname> <given-names>A</given-names></name><name><surname>Raimondi</surname> <given-names>A</given-names></name><name><surname>Tacchetti</surname> <given-names>C</given-names></name><name><surname>Kuchay</surname> <given-names>S</given-names></name><name><surname>Pass</surname> <given-names>HI</given-names></name><name><surname>Affar</surname> <given-names>EB</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Pinton</surname> <given-names>P</given-names></name><name><surname>Carbone</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation</article-title><source>Nature</source><volume>77</volume><fpage>549</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1038/nature22798</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borden</surname> <given-names>EC</given-names></name><name><surname>Sen</surname> <given-names>GC</given-names></name><name><surname>Uze</surname> <given-names>G</given-names></name><name><surname>Silverman</surname> <given-names>RH</given-names></name><name><surname>Ransohoff</surname> <given-names>RM</given-names></name><name><surname>Foster</surname> <given-names>GR</given-names></name><name><surname>Stark</surname> <given-names>GR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Interferons at age 50: past, current and future impact on biomedicine</article-title><source>Nature Reviews Drug Discovery</source><volume>6</volume><fpage>975</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1038/nrd2422</pub-id><pub-id pub-id-type="pmid">18049472</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname> <given-names>MJ</given-names></name><name><surname>Raaijmakers</surname> <given-names>LM</given-names></name><name><surname>Ramakrishnan</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Valiyaparambil</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Nowak</surname> <given-names>NJ</given-names></name><name><surname>Pili</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma</article-title><source>Oncogene</source><volume>33</volume><fpage>4961</fpage><lpage>4965</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.455</pub-id><pub-id pub-id-type="pmid">24186201</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Comprehensive molecular characterization of clear cell renal cell carcinoma</article-title><source>Nature</source><volume>499</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/nature12222</pub-id><pub-id pub-id-type="pmid">23792563</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>S-M</given-names></name><name><surname>Lu</surname> <given-names>M</given-names></name><name><surname>Cheung</surname> <given-names>WKC</given-names></name><name><surname>Cai</surname> <given-names>W</given-names></name><name><surname>Gale</surname> <given-names>M</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Yan</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting</article-title><source>Nucleic Acids Research</source><volume>60</volume><elocation-id>gkw660</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkw660</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Xia</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Han</surname> <given-names>D</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Cao</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Methyltransferase SETD2-Mediated methylation of STAT1 is critical for interferon antiviral activity</article-title><source>Cell</source><volume>170</volume><fpage>492</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.042</pub-id><pub-id pub-id-type="pmid">28753426</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheon</surname> <given-names>H</given-names></name><name><surname>Holvey-Bates</surname> <given-names>EG</given-names></name><name><surname>Schoggins</surname> <given-names>JW</given-names></name><name><surname>Forster</surname> <given-names>S</given-names></name><name><surname>Hertzog</surname> <given-names>P</given-names></name><name><surname>Imanaka</surname> <given-names>N</given-names></name><name><surname>Rice</surname> <given-names>CM</given-names></name><name><surname>Jackson</surname> <given-names>MW</given-names></name><name><surname>Junk</surname> <given-names>DJ</given-names></name><name><surname>Stark</surname> <given-names>GR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage</article-title><source>The EMBO Journal</source><volume>32</volume><fpage>2751</fpage><lpage>2763</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.203</pub-id><pub-id pub-id-type="pmid">24065129</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname> <given-names>M</given-names></name><name><surname>Talarchek</surname> <given-names>J</given-names></name><name><surname>Schindeler</surname> <given-names>K</given-names></name><name><surname>Saraiva</surname> <given-names>E</given-names></name><name><surname>Penney</surname> <given-names>LS</given-names></name><name><surname>Ludman</surname> <given-names>M</given-names></name><name><surname>Testa</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma</article-title><source>Cancer Genetics</source><volume>206</volume><fpage>206</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2013.05.018</pub-id><pub-id pub-id-type="pmid">23849051</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Chustecka</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><source>Immunotherapy Changes First-Line Paradigm in Advanced RCC</source><publisher-name>Medscape</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.medscape.com/slideshow/compensation-2017-neurology-6008575">https://www.medscape.com/slideshow/compensation-2017-neurology-6008575</ext-link></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa-Pereira</surname> <given-names>AP</given-names></name><name><surname>Tininini</surname> <given-names>S</given-names></name><name><surname>Strobl</surname> <given-names>B</given-names></name><name><surname>Alonzi</surname> <given-names>T</given-names></name><name><surname>Schlaak</surname> <given-names>JF</given-names></name><name><surname>Is'harc</surname> <given-names>H</given-names></name><name><surname>Gesualdo</surname> <given-names>I</given-names></name><name><surname>Newman</surname> <given-names>SJ</given-names></name><name><surname>Kerr</surname> <given-names>IM</given-names></name><name><surname>Poli</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mutational switch of an IL-6 response to an interferon-gamma-like response</article-title><source>PNAS</source><volume>99</volume><fpage>8043</fpage><lpage>8047</lpage><pub-id pub-id-type="doi">10.1073/pnas.122236099</pub-id><pub-id pub-id-type="pmid">12060750</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalgliesh</surname> <given-names>GL</given-names></name><name><surname>Furge</surname> <given-names>K</given-names></name><name><surname>Greenman</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Bignell</surname> <given-names>G</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Edkins</surname> <given-names>S</given-names></name><name><surname>Hardy</surname> <given-names>C</given-names></name><name><surname>Latimer</surname> <given-names>C</given-names></name><name><surname>Teague</surname> <given-names>J</given-names></name><name><surname>Andrews</surname> <given-names>J</given-names></name><name><surname>Barthorpe</surname> <given-names>S</given-names></name><name><surname>Beare</surname> <given-names>D</given-names></name><name><surname>Buck</surname> <given-names>G</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Forbes</surname> <given-names>S</given-names></name><name><surname>Jia</surname> <given-names>M</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Knott</surname> <given-names>H</given-names></name><name><surname>Kok</surname> <given-names>CY</given-names></name><name><surname>Lau</surname> <given-names>KW</given-names></name><name><surname>Leroy</surname> <given-names>C</given-names></name><name><surname>Lin</surname> <given-names>ML</given-names></name><name><surname>McBride</surname> <given-names>DJ</given-names></name><name><surname>Maddison</surname> <given-names>M</given-names></name><name><surname>Maguire</surname> <given-names>S</given-names></name><name><surname>McLay</surname> <given-names>K</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>Mironenko</surname> <given-names>T</given-names></name><name><surname>Mulderrig</surname> <given-names>L</given-names></name><name><surname>Mudie</surname> <given-names>L</given-names></name><name><surname>O'Meara</surname> <given-names>S</given-names></name><name><surname>Pleasance</surname> <given-names>E</given-names></name><name><surname>Rajasingham</surname> <given-names>A</given-names></name><name><surname>Shepherd</surname> <given-names>R</given-names></name><name><surname>Smith</surname> <given-names>R</given-names></name><name><surname>Stebbings</surname> <given-names>L</given-names></name><name><surname>Stephens</surname> <given-names>P</given-names></name><name><surname>Tang</surname> <given-names>G</given-names></name><name><surname>Tarpey</surname> <given-names>PS</given-names></name><name><surname>Turrell</surname> <given-names>K</given-names></name><name><surname>Dykema</surname> <given-names>KJ</given-names></name><name><surname>Khoo</surname> <given-names>SK</given-names></name><name><surname>Petillo</surname> <given-names>D</given-names></name><name><surname>Wondergem</surname> <given-names>B</given-names></name><name><surname>Anema</surname> <given-names>J</given-names></name><name><surname>Kahnoski</surname> <given-names>RJ</given-names></name><name><surname>Teh</surname> <given-names>BT</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes</article-title><source>Nature</source><volume>463</volume><fpage>360</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1038/nature08672</pub-id><pub-id pub-id-type="pmid">20054297</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daou</surname> <given-names>S</given-names></name><name><surname>Hammond-Martel</surname> <given-names>I</given-names></name><name><surname>Mashtalir</surname> <given-names>N</given-names></name><name><surname>Barbour</surname> <given-names>H</given-names></name><name><surname>Gagnon</surname> <given-names>J</given-names></name><name><surname>Iannantuono</surname> <given-names>NV</given-names></name><name><surname>Nkwe</surname> <given-names>NS</given-names></name><name><surname>Motorina</surname> <given-names>A</given-names></name><name><surname>Pak</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Wurtele</surname> <given-names>H</given-names></name><name><surname>Milot</surname> <given-names>E</given-names></name><name><surname>Mallette</surname> <given-names>FA</given-names></name><name><surname>Carbone</surname> <given-names>M</given-names></name><name><surname>Affar</surname> <given-names>elB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The BAP1/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in Cancer</article-title><source>Journal of Biological Chemistry</source><volume>290</volume><fpage>28643</fpage><lpage>28663</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.661553</pub-id><pub-id pub-id-type="pmid">26416890</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Xiao</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name><name><surname>Kaelin</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL<sup>-/</sup>- clear cell renal carcinoma</article-title><source>PNAS</source><volume>114</volume><fpage>1027</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1073/pnas.1619726114</pub-id><pub-id pub-id-type="pmid">28082722</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlinger</surname> <given-names>M</given-names></name><name><surname>Rowan</surname> <given-names>AJ</given-names></name><name><surname>Horswell</surname> <given-names>S</given-names></name><name><surname>Math</surname> <given-names>M</given-names></name><name><surname>Larkin</surname> <given-names>J</given-names></name><name><surname>Endesfelder</surname> <given-names>D</given-names></name><name><surname>Gronroos</surname> <given-names>E</given-names></name><name><surname>Martinez</surname> <given-names>P</given-names></name><name><surname>Matthews</surname> <given-names>N</given-names></name><name><surname>Stewart</surname> <given-names>A</given-names></name><name><surname>Tarpey</surname> <given-names>P</given-names></name><name><surname>Varela</surname> <given-names>I</given-names></name><name><surname>Phillimore</surname> <given-names>B</given-names></name><name><surname>Begum</surname> <given-names>S</given-names></name><name><surname>McDonald</surname> <given-names>NQ</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Latimer</surname> <given-names>C</given-names></name><name><surname>Santos</surname> <given-names>CR</given-names></name><name><surname>Nohadani</surname> <given-names>M</given-names></name><name><surname>Eklund</surname> <given-names>AC</given-names></name><name><surname>Spencer-Dene</surname> <given-names>B</given-names></name><name><surname>Clark</surname> <given-names>G</given-names></name><name><surname>Pickering</surname> <given-names>L</given-names></name><name><surname>Stamp</surname> <given-names>G</given-names></name><name><surname>Gore</surname> <given-names>M</given-names></name><name><surname>Szallasi</surname> <given-names>Z</given-names></name><name><surname>Downward</surname> <given-names>J</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</article-title><source>New England Journal of Medicine</source><volume>366</volume><fpage>883</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113205</pub-id><pub-id pub-id-type="pmid">22397650</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlinger</surname> <given-names>M</given-names></name><name><surname>Horswell</surname> <given-names>S</given-names></name><name><surname>Larkin</surname> <given-names>J</given-names></name><name><surname>Rowan</surname> <given-names>AJ</given-names></name><name><surname>Salm</surname> <given-names>MP</given-names></name><name><surname>Varela</surname> <given-names>I</given-names></name><name><surname>Fisher</surname> <given-names>R</given-names></name><name><surname>McGranahan</surname> <given-names>N</given-names></name><name><surname>Matthews</surname> <given-names>N</given-names></name><name><surname>Santos</surname> <given-names>CR</given-names></name><name><surname>Martinez</surname> <given-names>P</given-names></name><name><surname>Phillimore</surname> <given-names>B</given-names></name><name><surname>Begum</surname> <given-names>S</given-names></name><name><surname>Rabinowitz</surname> <given-names>A</given-names></name><name><surname>Spencer-Dene</surname> <given-names>B</given-names></name><name><surname>Gulati</surname> <given-names>S</given-names></name><name><surname>Bates</surname> <given-names>PA</given-names></name><name><surname>Stamp</surname> <given-names>G</given-names></name><name><surname>Pickering</surname> <given-names>L</given-names></name><name><surname>Gore</surname> <given-names>M</given-names></name><name><surname>Nicol</surname> <given-names>DL</given-names></name><name><surname>Hazell</surname> <given-names>S</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Stewart</surname> <given-names>A</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing</article-title><source>Nature Genetics</source><volume>46</volume><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/ng.2891</pub-id><pub-id pub-id-type="pmid">24487277</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>YF</given-names></name><name><surname>Cohn</surname> <given-names>S</given-names></name><name><surname>Christie</surname> <given-names>A</given-names></name><name><surname>McKenzie</surname> <given-names>T</given-names></name><name><surname>Wolff</surname> <given-names>N</given-names></name><name><surname>Do</surname> <given-names>QN</given-names></name><name><surname>Madhuranthakam</surname> <given-names>AJ</given-names></name><name><surname>Pedrosa</surname> <given-names>I</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Dey</surname> <given-names>A</given-names></name><name><surname>Busslinger</surname> <given-names>M</given-names></name><name><surname>Xie</surname> <given-names>XJ</given-names></name><name><surname>Hammer</surname> <given-names>RE</given-names></name><name><surname>McKay</surname> <given-names>RM</given-names></name><name><surname>Kapur</surname> <given-names>P</given-names></name><name><surname>Brugarolas</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Modeling renal cell carcinoma in mice: <italic>Bap1</italic> and <italic>Pbrm1</italic> Inactivation Drive Tumor Grade</article-title><source>Cancer Discovery</source><volume>7</volume><fpage>900</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0292</pub-id><pub-id pub-id-type="pmid">28473526</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>G</given-names></name><name><surname>Gui</surname> <given-names>Y</given-names></name><name><surname>Gao</surname> <given-names>S</given-names></name><name><surname>Tang</surname> <given-names>A</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Jia</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>He</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Song</surname> <given-names>P</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Liang</surname> <given-names>C</given-names></name><name><surname>Wan</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Jian</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Ye</surname> <given-names>R</given-names></name><name><surname>Huang</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Zou</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>Z</given-names></name><name><surname>Wu</surname> <given-names>R</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Fan</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Yin</surname> <given-names>W</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>B</given-names></name><name><surname>Feng</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Xie</surname> <given-names>J</given-names></name><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Kristiansen</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Cai</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma</article-title><source>Nature Genetics</source><volume>44</volume><fpage>17</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1038/ng.1014</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakimi</surname> <given-names>AA</given-names></name><name><surname>Ostrovnaya</surname> <given-names>I</given-names></name><name><surname>Reva</surname> <given-names>B</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Chen</surname> <given-names>YB</given-names></name><name><surname>Gonen</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Takeda</surname> <given-names>S</given-names></name><name><surname>Voss</surname> <given-names>MH</given-names></name><name><surname>Tickoo</surname> <given-names>SK</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name><name><surname>Russo</surname> <given-names>P</given-names></name><name><surname>Cheng</surname> <given-names>EH</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Motzer</surname> <given-names>RJ</given-names></name><name><surname>Hsieh</surname> <given-names>JJ</given-names></name><collab>ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network</article-title><source>Clinical Cancer Research</source><volume>19</volume><fpage>3259</fpage><lpage>3267</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3886</pub-id><pub-id pub-id-type="pmid">23620406</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname> <given-names>D</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of Cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname> <given-names>PC</given-names></name><name><surname>Behrmann</surname> <given-names>I</given-names></name><name><surname>Müller-Newen</surname> <given-names>G</given-names></name><name><surname>Schaper</surname> <given-names>F</given-names></name><name><surname>Graeve</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway</article-title><source>Biochemical Journal</source><volume>334</volume><fpage>297</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1042/bj3340297</pub-id><pub-id pub-id-type="pmid">9716487</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname> <given-names>JJ</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>PI</given-names></name><name><surname>Marker</surname> <given-names>M</given-names></name><name><surname>Redzematovic</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>YB</given-names></name><name><surname>Selcuklu</surname> <given-names>SD</given-names></name><name><surname>Weinhold</surname> <given-names>N</given-names></name><name><surname>Bouvier</surname> <given-names>N</given-names></name><name><surname>Huberman</surname> <given-names>KH</given-names></name><name><surname>Bhanot</surname> <given-names>U</given-names></name><name><surname>Chevinsky</surname> <given-names>MS</given-names></name><name><surname>Patel</surname> <given-names>P</given-names></name><name><surname>Pinciroli</surname> <given-names>P</given-names></name><name><surname>Won</surname> <given-names>HH</given-names></name><name><surname>You</surname> <given-names>D</given-names></name><name><surname>Viale</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>W</given-names></name><name><surname>Hakimi</surname> <given-names>AA</given-names></name><name><surname>Berger</surname> <given-names>MF</given-names></name><name><surname>Socci</surname> <given-names>ND</given-names></name><name><surname>Cheng</surname> <given-names>EH</given-names></name><name><surname>Knox</surname> <given-names>J</given-names></name><name><surname>Voss</surname> <given-names>MH</given-names></name><name><surname>Voi</surname> <given-names>M</given-names></name><name><surname>Motzer</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genomic biomarkers of a randomized trial comparing First-line everolimus and sunitinib in patients with metastatic renal cell carcinoma</article-title><source>European Urology</source><volume>71</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2016.10.007</pub-id><pub-id pub-id-type="pmid">27751729</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>daW</given-names></name><name><surname>Sherman</surname> <given-names>BT</given-names></name><name><surname>Lempicki</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nature Protocols</source><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Jacobsen</surname> <given-names>A</given-names></name><collab>cBioPortal Questions</collab></person-group><year iso-8601-date="2018">2018</year><data-title>cgdsr: R-Based API for Accessing the MSKCC Cancer Genomics Data Server (CGDS)</data-title><source>R Package Version</source><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=cgdsr">https://CRAN.R-project.org/package=cgdsr</ext-link></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Dulaimi</surname> <given-names>E</given-names></name><name><surname>Devarajan</surname> <given-names>K</given-names></name><name><surname>Parsons</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Liao</surname> <given-names>L</given-names></name><name><surname>Cho</surname> <given-names>EA</given-names></name><name><surname>O'Neill</surname> <given-names>R</given-names></name><name><surname>Solomides</surname> <given-names>C</given-names></name><name><surname>Peiper</surname> <given-names>SC</given-names></name><name><surname>Testa</surname> <given-names>JR</given-names></name><name><surname>Uzzo</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma</article-title><source>PloS ONE</source><volume>11</volume><elocation-id>e0164554</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0164554</pub-id><pub-id pub-id-type="pmid">27764136</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Dulaimi</surname> <given-names>E</given-names></name><name><surname>Devarajan</surname> <given-names>K</given-names></name><name><surname>Parsons</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>O'Neill</surname> <given-names>R</given-names></name><name><surname>Solomides</surname> <given-names>C</given-names></name><name><surname>Peiper</surname> <given-names>SC</given-names></name><name><surname>Testa</surname> <given-names>JR</given-names></name><name><surname>Uzzo</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma</article-title><source>Oncotarget</source><volume>8</volume><elocation-id>16965</elocation-id><pub-id pub-id-type="doi">10.18632/oncotarget.16965</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>WE</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Rabinovic</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Adjusting batch effects in microarray expression data using empirical bayes methods</article-title><source>Biostatistics</source><volume>8</volume><fpage>118</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxj037</pub-id><pub-id pub-id-type="pmid">16632515</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname> <given-names>RW</given-names></name><name><surname>Kapur</surname> <given-names>P</given-names></name><name><surname>Serie</surname> <given-names>DJ</given-names></name><name><surname>Eckel-Passow</surname> <given-names>JE</given-names></name><name><surname>Parasramka</surname> <given-names>M</given-names></name><name><surname>Ho</surname> <given-names>T</given-names></name><name><surname>Cheville</surname> <given-names>JC</given-names></name><name><surname>Frenkel</surname> <given-names>E</given-names></name><name><surname>Rakheja</surname> <given-names>D</given-names></name><name><surname>Brugarolas</surname> <given-names>J</given-names></name><name><surname>Parker</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma</article-title><source>Cancer</source><volume>120</volume><fpage>1059</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1002/cncr.28521</pub-id><pub-id pub-id-type="pmid">24382589</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname> <given-names>RW</given-names></name><name><surname>Kapur</surname> <given-names>P</given-names></name><name><surname>Serie</surname> <given-names>DJ</given-names></name><name><surname>Parasramka</surname> <given-names>M</given-names></name><name><surname>Ho</surname> <given-names>TH</given-names></name><name><surname>Cheville</surname> <given-names>JC</given-names></name><name><surname>Frenkel</surname> <given-names>E</given-names></name><name><surname>Parker</surname> <given-names>AS</given-names></name><name><surname>Brugarolas</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression</article-title><source>The Journal of Urology</source><volume>195</volume><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2015.07.113</pub-id><pub-id pub-id-type="pmid">26300218</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaelin</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The Von Hippel-Lindau tumor suppressor protein: roles in Cancer and oxygen sensing</article-title><source>Cold Spring Harbor Symposia on Quantitative Biology</source><volume>70</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1101/sqb.2005.70.001</pub-id><pub-id pub-id-type="pmid">16869749</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kassambara</surname> <given-names>A</given-names></name><name><surname>Kosinski</surname> <given-names>M</given-names></name><name><surname>Biecek</surname> <given-names>P</given-names></name><name><surname>Fabian</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Marcin survminer: Drawing Survival Curves using 'ggplot2'</data-title><source>R Package Version</source><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=survminer">https://CRAN.R-project.org/package=survminer</ext-link></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname> <given-names>K</given-names></name><name><surname>Klco</surname> <given-names>J</given-names></name><name><surname>Nakamura</surname> <given-names>E</given-names></name><name><surname>Lechpammer</surname> <given-names>M</given-names></name><name><surname>Kaelin</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein</article-title><source>Cancer Cell</source><volume>1</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00043-0</pub-id><pub-id pub-id-type="pmid">12086860</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>L</given-names></name><name><surname>Testa</surname> <given-names>JR</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer</article-title><source>Cancer Genetics</source><volume>208</volume><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2015.02.008</pub-id><pub-id pub-id-type="pmid">25873528</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linehan</surname> <given-names>WM</given-names></name><name><surname>Vasselli</surname> <given-names>J</given-names></name><name><surname>Srinivasan</surname> <given-names>R</given-names></name><name><surname>Walther</surname> <given-names>MM</given-names></name><name><surname>Merino</surname> <given-names>M</given-names></name><name><surname>Choyke</surname> <given-names>P</given-names></name><name><surname>Vocke</surname> <given-names>C</given-names></name><name><surname>Schmidt</surname> <given-names>L</given-names></name><name><surname>Isaacs</surname> <given-names>JS</given-names></name><name><surname>Glenn</surname> <given-names>G</given-names></name><name><surname>Toro</surname> <given-names>J</given-names></name><name><surname>Zbar</surname> <given-names>B</given-names></name><name><surname>Bottaro</surname> <given-names>D</given-names></name><name><surname>Neckers</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Genetic basis of Cancer of the kidney: disease-specific approaches to therapy</article-title><source>Clinical Cancer Research</source><volume>10</volume><fpage>6282S</fpage><lpage>6289</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-050013</pub-id><pub-id pub-id-type="pmid">15448018</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>L</given-names></name><name><surname>Zhu</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Drennan</surname> <given-names>AC</given-names></name><name><surname>Kimpara</surname> <given-names>S</given-names></name><name><surname>Rumball</surname> <given-names>I</given-names></name><name><surname>Selzer</surname> <given-names>C</given-names></name><name><surname>Cameron</surname> <given-names>H</given-names></name><name><surname>Kellicut</surname> <given-names>A</given-names></name><name><surname>Kelm</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Waldmann</surname> <given-names>TA</given-names></name><name><surname>Rui</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma</article-title><source>PNAS</source><volume>115</volume><fpage>E498</fpage><lpage>E505</lpage><pub-id pub-id-type="doi">10.1073/pnas.1715118115</pub-id><pub-id pub-id-type="pmid">29295936</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maritano</surname> <given-names>D</given-names></name><name><surname>Sugrue</surname> <given-names>ML</given-names></name><name><surname>Tininini</surname> <given-names>S</given-names></name><name><surname>Dewilde</surname> <given-names>S</given-names></name><name><surname>Strobl</surname> <given-names>B</given-names></name><name><surname>Fu</surname> <given-names>X</given-names></name><name><surname>Murray-Tait</surname> <given-names>V</given-names></name><name><surname>Chiarle</surname> <given-names>R</given-names></name><name><surname>Poli</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The STAT3 isoforms alpha and beta have unique and specific functions</article-title><source>Nature Immunology</source><volume>5</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1038/ni1052</pub-id><pub-id pub-id-type="pmid">15021879</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname> <given-names>D</given-names></name><name><surname>Margolis</surname> <given-names>CA</given-names></name><name><surname>Gao</surname> <given-names>W</given-names></name><name><surname>Voss</surname> <given-names>MH</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Martini</surname> <given-names>DJ</given-names></name><name><surname>Norton</surname> <given-names>C</given-names></name><name><surname>Bossé</surname> <given-names>D</given-names></name><name><surname>Wankowicz</surname> <given-names>SM</given-names></name><name><surname>Cullen</surname> <given-names>D</given-names></name><name><surname>Horak</surname> <given-names>C</given-names></name><name><surname>Wind-Rotolo</surname> <given-names>M</given-names></name><name><surname>Tracy</surname> <given-names>A</given-names></name><name><surname>Giannakis</surname> <given-names>M</given-names></name><name><surname>Hodi</surname> <given-names>FS</given-names></name><name><surname>Drake</surname> <given-names>CG</given-names></name><name><surname>Ball</surname> <given-names>MW</given-names></name><name><surname>Allaf</surname> <given-names>ME</given-names></name><name><surname>Snyder</surname> <given-names>A</given-names></name><name><surname>Hellmann</surname> <given-names>MD</given-names></name><name><surname>Ho</surname> <given-names>T</given-names></name><name><surname>Motzer</surname> <given-names>RJ</given-names></name><name><surname>Signoretti</surname> <given-names>S</given-names></name><name><surname>Kaelin</surname> <given-names>WG</given-names></name><name><surname>Choueiri</surname> <given-names>TK</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma</article-title><source>Science</source><volume>359</volume><fpage>801</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1126/science.aan5951</pub-id><pub-id pub-id-type="pmid">29301960</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nargund</surname> <given-names>AM</given-names></name><name><surname>Pham</surname> <given-names>CG</given-names></name><name><surname>Dong</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>PI</given-names></name><name><surname>Osmangeyoglu</surname> <given-names>HU</given-names></name><name><surname>Xie</surname> <given-names>Y</given-names></name><name><surname>Aras</surname> <given-names>O</given-names></name><name><surname>Han</surname> <given-names>S</given-names></name><name><surname>Oyama</surname> <given-names>T</given-names></name><name><surname>Takeda</surname> <given-names>S</given-names></name><name><surname>Ray</surname> <given-names>CE</given-names></name><name><surname>Dong</surname> <given-names>Z</given-names></name><name><surname>Berge</surname> <given-names>M</given-names></name><name><surname>Hakimi</surname> <given-names>AA</given-names></name><name><surname>Monette</surname> <given-names>S</given-names></name><name><surname>Lekaye</surname> <given-names>CL</given-names></name><name><surname>Koutcher</surname> <given-names>JA</given-names></name><name><surname>Leslie</surname> <given-names>CS</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name><name><surname>Weinhold</surname> <given-names>N</given-names></name><name><surname>Lee</surname> <given-names>W</given-names></name><name><surname>Tickoo</surname> <given-names>SK</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Cheng</surname> <given-names>EH</given-names></name><name><surname>Hsieh</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The SWI/SNF protein PBRM1 restrains VHL-Loss-Driven clear cell renal cell carcinoma</article-title><source>Cell Reports</source><volume>18</volume><fpage>2893</fpage><lpage>2906</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.02.074</pub-id><pub-id pub-id-type="pmid">28329682</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negrotto</surname> <given-names>S</given-names></name><name><surname>Hu</surname> <given-names>Z</given-names></name><name><surname>Alcazar</surname> <given-names>O</given-names></name><name><surname>Ng</surname> <given-names>KP</given-names></name><name><surname>Triozzi</surname> <given-names>P</given-names></name><name><surname>Lindner</surname> <given-names>D</given-names></name><name><surname>Rini</surname> <given-names>B</given-names></name><name><surname>Saunthararajah</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Noncytotoxic differentiation treatment of renal cell Cancer</article-title><source>Cancer Research</source><volume>71</volume><fpage>1431</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2422</pub-id><pub-id pub-id-type="pmid">21303982</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Liao</surname> <given-names>L</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Lindner</surname> <given-names>DJ</given-names></name><name><surname>Zhou</surname> <given-names>M</given-names></name><name><surname>Rini</surname> <given-names>B</given-names></name><name><surname>Yan</surname> <given-names>Q</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The Von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C</article-title><source>Oncogene</source><volume>31</volume><fpage>776</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.266</pub-id><pub-id pub-id-type="pmid">21725364</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname> <given-names>D</given-names></name><name><surname>Kobayashi</surname> <given-names>A</given-names></name><name><surname>Jiang</surname> <given-names>P</given-names></name><name><surname>Ferrari de Andrade</surname> <given-names>L</given-names></name><name><surname>Tay</surname> <given-names>RE</given-names></name><name><surname>Luoma</surname> <given-names>AM</given-names></name><name><surname>Tsoucas</surname> <given-names>D</given-names></name><name><surname>Qiu</surname> <given-names>X</given-names></name><name><surname>Lim</surname> <given-names>K</given-names></name><name><surname>Rao</surname> <given-names>P</given-names></name><name><surname>Long</surname> <given-names>HW</given-names></name><name><surname>Yuan</surname> <given-names>GC</given-names></name><name><surname>Doench</surname> <given-names>J</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name><name><surname>Wucherpfennig</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Major chromatin regulator determines resistance of tumor cells to T cell-mediated killing</article-title><source>Science</source><volume>359</volume><fpage>770</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1126/science.aao1710</pub-id><pub-id pub-id-type="pmid">29301958</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>IY</given-names></name><name><surname>Powell</surname> <given-names>RT</given-names></name><name><surname>Tripathi</surname> <given-names>DN</given-names></name><name><surname>Dere</surname> <given-names>R</given-names></name><name><surname>Ho</surname> <given-names>TH</given-names></name><name><surname>Blasius</surname> <given-names>TL</given-names></name><name><surname>Chiang</surname> <given-names>YC</given-names></name><name><surname>Davis</surname> <given-names>IJ</given-names></name><name><surname>Fahey</surname> <given-names>CC</given-names></name><name><surname>Hacker</surname> <given-names>KE</given-names></name><name><surname>Verhey</surname> <given-names>KJ</given-names></name><name><surname>Bedford</surname> <given-names>MT</given-names></name><name><surname>Jonasch</surname> <given-names>E</given-names></name><name><surname>Rathmell</surname> <given-names>WK</given-names></name><name><surname>Walker</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dual chromatin and cytoskeletal remodeling by SETD2</article-title><source>Cell</source><volume>166</volume><fpage>950</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.005</pub-id><pub-id pub-id-type="pmid">27518565</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peña-Llopis</surname> <given-names>S</given-names></name><name><surname>Vega-Rubín-de-Celis</surname> <given-names>S</given-names></name><name><surname>Liao</surname> <given-names>A</given-names></name><name><surname>Leng</surname> <given-names>N</given-names></name><name><surname>Pavía-Jiménez</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Yamasaki</surname> <given-names>T</given-names></name><name><surname>Zhrebker</surname> <given-names>L</given-names></name><name><surname>Sivanand</surname> <given-names>S</given-names></name><name><surname>Spence</surname> <given-names>P</given-names></name><name><surname>Kinch</surname> <given-names>L</given-names></name><name><surname>Hambuch</surname> <given-names>T</given-names></name><name><surname>Jain</surname> <given-names>S</given-names></name><name><surname>Lotan</surname> <given-names>Y</given-names></name><name><surname>Margulis</surname> <given-names>V</given-names></name><name><surname>Sagalowsky</surname> <given-names>AI</given-names></name><name><surname>Summerour</surname> <given-names>PB</given-names></name><name><surname>Kabbani</surname> <given-names>W</given-names></name><name><surname>Wong</surname> <given-names>SW</given-names></name><name><surname>Grishin</surname> <given-names>N</given-names></name><name><surname>Laurent</surname> <given-names>M</given-names></name><name><surname>Xie</surname> <given-names>XJ</given-names></name><name><surname>Haudenschild</surname> <given-names>CD</given-names></name><name><surname>Ross</surname> <given-names>MT</given-names></name><name><surname>Bentley</surname> <given-names>DR</given-names></name><name><surname>Kapur</surname> <given-names>P</given-names></name><name><surname>Brugarolas</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>BAP1 loss defines a new class of renal cell carcinoma</article-title><source>Nature Genetics</source><volume>44</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1038/ng.2323</pub-id><pub-id pub-id-type="pmid">22683710</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phipson</surname> <given-names>B</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Majewski</surname> <given-names>IJ</given-names></name><name><surname>Alexander</surname> <given-names>WS</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression</article-title><source>The Annals of Applied Statistics</source><volume>10</volume><fpage>946</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1214/16-AOAS920</pub-id><pub-id pub-id-type="pmid">28367255</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilarski</surname> <given-names>R</given-names></name><name><surname>Cebulla</surname> <given-names>CM</given-names></name><name><surname>Massengill</surname> <given-names>JB</given-names></name><name><surname>Rai</surname> <given-names>K</given-names></name><name><surname>Rich</surname> <given-names>T</given-names></name><name><surname>Strong</surname> <given-names>L</given-names></name><name><surname>McGillivray</surname> <given-names>B</given-names></name><name><surname>Asrat</surname> <given-names>M-J</given-names></name><name><surname>Davidorf</surname> <given-names>FH</given-names></name><name><surname>Abdel-Rahman</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Expanding the clinical phenotype of hereditary <italic>BAP1</italic> cancer predisposition syndrome, reporting three new cases</article-title><source>Genes, Chromosomes and Cancer</source><volume>53</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1002/gcc.22129</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regis</surname> <given-names>G</given-names></name><name><surname>Pensa</surname> <given-names>S</given-names></name><name><surname>Boselli</surname> <given-names>D</given-names></name><name><surname>Novelli</surname> <given-names>F</given-names></name><name><surname>Poli</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ups and downs: the STAT1:stat3 seesaw of interferon and gp130 receptor signalling</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>19</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2008.06.004</pub-id><pub-id pub-id-type="pmid">18620071</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Rini</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ipi/Nivo is the New Standard of Care in mRCC</article-title><source> Practiceupdate</source><ext-link ext-link-type="uri" xlink:href="https://www.practiceupdate.com/author/brian-rini/1008">https://www.practiceupdate.com/author/brian-rini/1008</ext-link><date-in-citation iso-8601-date="2017-11-08">November 8, 2017</date-in-citation></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname> <given-names>ME</given-names></name><name><surname>Phipson</surname> <given-names>B</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Law</surname> <given-names>CW</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Shalem</surname> <given-names>O</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title><source>Nature Methods</source><volume>11</volume><fpage>783</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3047</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sankin</surname> <given-names>A</given-names></name><name><surname>Hakimi</surname> <given-names>AA</given-names></name><name><surname>Mikkilineni</surname> <given-names>N</given-names></name><name><surname>Ostrovnaya</surname> <given-names>I</given-names></name><name><surname>Silk</surname> <given-names>MT</given-names></name><name><surname>Liang</surname> <given-names>Y</given-names></name><name><surname>Mano</surname> <given-names>R</given-names></name><name><surname>Chevinsky</surname> <given-names>M</given-names></name><name><surname>Motzer</surname> <given-names>RJ</given-names></name><name><surname>Solomon</surname> <given-names>SB</given-names></name><name><surname>Cheng</surname> <given-names>EH</given-names></name><name><surname>Durack</surname> <given-names>JC</given-names></name><name><surname>Coleman</surname> <given-names>JA</given-names></name><name><surname>Russo</surname> <given-names>P</given-names></name><name><surname>Hsieh</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling</article-title><source>Cancer Medicine</source><volume>3</volume><fpage>1485</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1002/cam4.293</pub-id><pub-id pub-id-type="pmid">25124064</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>Y</given-names></name><name><surname>Yoshizato</surname> <given-names>T</given-names></name><name><surname>Shiraishi</surname> <given-names>Y</given-names></name><name><surname>Maekawa</surname> <given-names>S</given-names></name><name><surname>Okuno</surname> <given-names>Y</given-names></name><name><surname>Kamura</surname> <given-names>T</given-names></name><name><surname>Shimamura</surname> <given-names>T</given-names></name><name><surname>Sato-Otsubo</surname> <given-names>A</given-names></name><name><surname>Nagae</surname> <given-names>G</given-names></name><name><surname>Suzuki</surname> <given-names>H</given-names></name><name><surname>Nagata</surname> <given-names>Y</given-names></name><name><surname>Yoshida</surname> <given-names>K</given-names></name><name><surname>Kon</surname> <given-names>A</given-names></name><name><surname>Suzuki</surname> <given-names>Y</given-names></name><name><surname>Chiba</surname> <given-names>K</given-names></name><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Niida</surname> <given-names>A</given-names></name><name><surname>Fujimoto</surname> <given-names>A</given-names></name><name><surname>Tsunoda</surname> <given-names>T</given-names></name><name><surname>Morikawa</surname> <given-names>T</given-names></name><name><surname>Maeda</surname> <given-names>D</given-names></name><name><surname>Kume</surname> <given-names>H</given-names></name><name><surname>Sugano</surname> <given-names>S</given-names></name><name><surname>Fukayama</surname> <given-names>M</given-names></name><name><surname>Aburatani</surname> <given-names>H</given-names></name><name><surname>Sanada</surname> <given-names>M</given-names></name><name><surname>Miyano</surname> <given-names>S</given-names></name><name><surname>Homma</surname> <given-names>Y</given-names></name><name><surname>Ogawa</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrated molecular analysis of clear-cell renal cell carcinoma</article-title><source>Nature Genetics</source><volume>45</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1038/ng.2699</pub-id><pub-id pub-id-type="pmid">23797736</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalem</surname> <given-names>O</given-names></name><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Hartenian</surname> <given-names>E</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name><name><surname>Scott</surname> <given-names>DA</given-names></name><name><surname>Mikkelson</surname> <given-names>T</given-names></name><name><surname>Heckl</surname> <given-names>D</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Doench</surname> <given-names>JG</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title><source>Science</source><volume>343</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1126/science.1247005</pub-id><pub-id pub-id-type="pmid">24336571</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname> <given-names>JM</given-names></name><name><surname>Hacker</surname> <given-names>KE</given-names></name><name><surname>Singh</surname> <given-names>D</given-names></name><name><surname>Brannon</surname> <given-names>AR</given-names></name><name><surname>Parker</surname> <given-names>JS</given-names></name><name><surname>Weiser</surname> <given-names>M</given-names></name><name><surname>Ho</surname> <given-names>TH</given-names></name><name><surname>Kuan</surname> <given-names>PF</given-names></name><name><surname>Jonasch</surname> <given-names>E</given-names></name><name><surname>Furey</surname> <given-names>TS</given-names></name><name><surname>Prins</surname> <given-names>JF</given-names></name><name><surname>Lieb</surname> <given-names>JD</given-names></name><name><surname>Rathmell</surname> <given-names>WK</given-names></name><name><surname>Davis</surname> <given-names>IJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects</article-title><source>Genome Research</source><volume>24</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1101/gr.158253.113</pub-id><pub-id pub-id-type="pmid">24158655</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephanou</surname> <given-names>A</given-names></name><name><surname>Latchman</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>STAT-1: a novel regulator of apoptosis</article-title><source>International Journal of Experimental Pathology</source><volume>84</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1111/j.0959-9673.2003.00363.x</pub-id><pub-id pub-id-type="pmid">14748743</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Therneau</surname> <given-names>T</given-names></name><name><surname>Lumley</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><source>A Package for Survival Analysis in S. Version 2</source><publisher-name>Mayo Foundation</publisher-name><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=survival">https://CRAN.R-project.org/package=survival</ext-link></element-citation></ref><ref id="bib62"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Therneau</surname> <given-names>T</given-names></name><name><surname>Patricia</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2000">2000</year><source>Modeling Survival Data: Extending the Cox Model</source><publisher-name>Springer Science &amp; Business Media</publisher-name></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varela</surname> <given-names>I</given-names></name><name><surname>Tarpey</surname> <given-names>P</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Huang</surname> <given-names>D</given-names></name><name><surname>Ong</surname> <given-names>CK</given-names></name><name><surname>Stephens</surname> <given-names>P</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>ML</given-names></name><name><surname>Teague</surname> <given-names>J</given-names></name><name><surname>Bignell</surname> <given-names>G</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Cho</surname> <given-names>J</given-names></name><name><surname>Dalgliesh</surname> <given-names>GL</given-names></name><name><surname>Galappaththige</surname> <given-names>D</given-names></name><name><surname>Greenman</surname> <given-names>C</given-names></name><name><surname>Hardy</surname> <given-names>C</given-names></name><name><surname>Jia</surname> <given-names>M</given-names></name><name><surname>Latimer</surname> <given-names>C</given-names></name><name><surname>Lau</surname> <given-names>KW</given-names></name><name><surname>Marshall</surname> <given-names>J</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>Mudie</surname> <given-names>L</given-names></name><name><surname>Stebbings</surname> <given-names>L</given-names></name><name><surname>Largaespada</surname> <given-names>DA</given-names></name><name><surname>Wessels</surname> <given-names>LF</given-names></name><name><surname>Richard</surname> <given-names>S</given-names></name><name><surname>Kahnoski</surname> <given-names>RJ</given-names></name><name><surname>Anema</surname> <given-names>J</given-names></name><name><surname>Tuveson</surname> <given-names>DA</given-names></name><name><surname>Perez-Mancera</surname> <given-names>PA</given-names></name><name><surname>Mustonen</surname> <given-names>V</given-names></name><name><surname>Fischer</surname> <given-names>A</given-names></name><name><surname>Adams</surname> <given-names>DJ</given-names></name><name><surname>Rust</surname> <given-names>A</given-names></name><name><surname>Chan-on</surname> <given-names>W</given-names></name><name><surname>Subimerb</surname> <given-names>C</given-names></name><name><surname>Dykema</surname> <given-names>K</given-names></name><name><surname>Furge</surname> <given-names>K</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Teh</surname> <given-names>BT</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma</article-title><source>Nature</source><volume>469</volume><fpage>539</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/nature09639</pub-id><pub-id pub-id-type="pmid">21248752</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cancer genome landscapes</article-title><source>Science</source><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmid">23539594</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadt</surname> <given-names>K</given-names></name><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Chung</surname> <given-names>JY</given-names></name><name><surname>Kiilgaard</surname> <given-names>J</given-names></name><name><surname>Heegaard</surname> <given-names>S</given-names></name><name><surname>Drzewiecki</surname> <given-names>KT</given-names></name><name><surname>Trent</surname> <given-names>JM</given-names></name><name><surname>Hewitt</surname> <given-names>SM</given-names></name><name><surname>Hayward</surname> <given-names>NK</given-names></name><name><surname>Gerdes</surname> <given-names>AM</given-names></name><name><surname>Brown</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A cryptic <italic>BAP1</italic> splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>25</volume><fpage>815</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12006</pub-id><pub-id pub-id-type="pmid">22889334</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname> <given-names>EJ</given-names></name><name><surname>Carpenter</surname> <given-names>PB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Understanding the language of Lys36 methylation at histone H3</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>13</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/nrm3274</pub-id><pub-id pub-id-type="pmid">22266761</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weichselbaum</surname> <given-names>RR</given-names></name><name><surname>Ishwaran</surname> <given-names>H</given-names></name><name><surname>Yoon</surname> <given-names>T</given-names></name><name><surname>Nuyten</surname> <given-names>DS</given-names></name><name><surname>Baker</surname> <given-names>SW</given-names></name><name><surname>Khodarev</surname> <given-names>N</given-names></name><name><surname>Su</surname> <given-names>AW</given-names></name><name><surname>Shaikh</surname> <given-names>AY</given-names></name><name><surname>Roach</surname> <given-names>P</given-names></name><name><surname>Kreike</surname> <given-names>B</given-names></name><name><surname>Roizman</surname> <given-names>B</given-names></name><name><surname>Bergh</surname> <given-names>J</given-names></name><name><surname>Pawitan</surname> <given-names>Y</given-names></name><name><surname>van de Vijver</surname> <given-names>MJ</given-names></name><name><surname>Minn</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer</article-title><source>PNAS</source><volume>105</volume><fpage>18490</fpage><lpage>18495</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809242105</pub-id><pub-id pub-id-type="pmid">19001271</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Ggplot2: Elegant Graphics for Data Analysis</source><publisher-name>Springer</publisher-name></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>Q</given-names></name><name><surname>Bartz</surname> <given-names>S</given-names></name><name><surname>Mao</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Kaelin</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>2092</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1128/MCB.01514-06</pub-id><pub-id pub-id-type="pmid">17220275</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Mashtalir</surname> <given-names>N</given-names></name><name><surname>Daou</surname> <given-names>S</given-names></name><name><surname>Hammond-Martel</surname> <given-names>I</given-names></name><name><surname>Ross</surname> <given-names>J</given-names></name><name><surname>Sui</surname> <given-names>G</given-names></name><name><surname>Hart</surname> <given-names>GW</given-names></name><name><surname>Rauscher</surname> <given-names>FJ</given-names></name><name><surname>Drobetsky</surname> <given-names>E</given-names></name><name><surname>Milot</surname> <given-names>E</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Affar</surname> <given-names>elB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression</article-title><source>Molecular and Cellular Biology</source><volume>30</volume><fpage>5071</fpage><lpage>5085</lpage><pub-id pub-id-type="doi">10.1128/MCB.00396-10</pub-id><pub-id pub-id-type="pmid">20805357</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Pak</surname> <given-names>H</given-names></name><name><surname>Hammond-Martel</surname> <given-names>I</given-names></name><name><surname>Ghram</surname> <given-names>M</given-names></name><name><surname>Rodrigue</surname> <given-names>A</given-names></name><name><surname>Daou</surname> <given-names>S</given-names></name><name><surname>Barbour</surname> <given-names>H</given-names></name><name><surname>Corbeil</surname> <given-names>L</given-names></name><name><surname>Hébert</surname> <given-names>J</given-names></name><name><surname>Drobetsky</surname> <given-names>E</given-names></name><name><surname>Masson</surname> <given-names>JY</given-names></name><name><surname>Di Noia</surname> <given-names>JM</given-names></name><name><surname>Affar</surname> <given-names>elB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair</article-title><source>PNAS</source><volume>111</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1073/pnas.1309085110</pub-id><pub-id pub-id-type="pmid">24347639</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Niu</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Multiple regulation pathways and pivotal biological functions of STAT3 in cancer</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>17663</elocation-id><pub-id pub-id-type="doi">10.1038/srep17663</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Lu</surname> <given-names>W</given-names></name><name><surname>Dong</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice</article-title><source>Clinical Cancer Research : An Official Journal of the American Association for Cancer Research</source><volume>8</volume><fpage>2942</fpage><lpage>2951</lpage><pub-id pub-id-type="pmid">12231540</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The roles of VHL-Dependent ubiquitination in signaling and Cancer</article-title><source>Frontiers in Oncology</source><volume>2</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2012.00035</pub-id><pub-id pub-id-type="pmid">22649785</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Niu</surname> <given-names>X</given-names></name><name><surname>Liao</surname> <given-names>L</given-names></name><name><surname>Cho</surname> <given-names>EA</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The contributions of HIF-target genes to tumor growth in RCC</article-title><source>PLoS ONE</source><volume>8</volume><elocation-id>e80544</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0080544</pub-id><pub-id pub-id-type="pmid">24260413</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmer</surname> <given-names>M</given-names></name><name><surname>Doucette</surname> <given-names>D</given-names></name><name><surname>Siddiqui</surname> <given-names>N</given-names></name><name><surname>Iliopoulos</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors</article-title><source>Molecular Cancer Research : MCR</source><volume>2</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">14985465</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.37925.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Davidson</surname><given-names>Irwin</given-names></name><role>Reviewing Editor</role><aff><institution>Institut de Génétique et de Biologie Moléculaire et Cellulaire</institution><country>France</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Multiple Tumor Suppressors Regulate a HIF-dependent Negative Feedback Loop through ISGF3 in Kidney Cancer&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Irwin Davidson as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Jeffrey Settleman as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: James Hsieh (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This paper describes the role of secondary mutations in ccRCC cells affecting PBRM1, KDM5C, BAP1 and SETD2; multiple tumor suppressors frequently mutated in ccRCC that converge on a HIF-dependent negative feedback loop through ISGF3. ShRNA knockdown of these genes in ccRCC cells in vitro, taken as a surrogate for the normally observed inactivating mutations seen in human tumours, lowers the expression of the STAT1, STAT2 and/or IRF9 proteins that together form the ISGF3 transcription factor. The study shows that ISGF3 is a potent tumour suppressor that does not act principally through direct regulation of cell proliferation, but modulates the immune-infiltrate of the tumours in some undescribed way to affect tumour growth.</p><p>Essential revisions:</p><p>All three reviewers thought that this was an interesting study with novel and relevant conclusions, but they found a number of important issues that require serious attention in any revised version.</p><p>The experiments performed in this study used established ccRCC cell lines. To verify that the observations are relevant for human ccRCC, the authors should use TCGA ccRCC datasets to investigate expression of ISGF3 in human ccRCC and its prognostic impact. They should use the TCGA dataset to test the hypothesis that tumors with no PBRM1, BAP1, SETD2 and KDM5C have differential expression of ISGF3 components. It is also essential to show by immunostaining that ISGF3 subunits are really down-regulated in sections form human ccRCC where the above genes are inactivated. It is critical that the mechanisms described here using model cells lines and xenograft tumours are verified in one way or another in panels of human ccRCC.</p><p>The authors report that KDM5C and PBRM1 physically interact. Figure 4 shows that expression of FLAG-PBRM1 can precipitate endogenous KDM5C, but the opposite has not been shown by transfecting FLAG-KDM5C to pull down endogenous PBRM1. This should be further investigated. PBRM1 is a well characterized subunit of the PBAF complex. The results presented here suggest that KDM5C associates with PBAF through interactions with PBRM1. This is a potentially important finding, but should be confirmed. The authors should investigate whether tagged PBRM1 co-precipitates other subunits of the PBAF complex and they should verify whether tagged KDM5C can precipitate additional subunits of the PBAF complex. In particular, they should exclude the possibility that these proteins interact when overexpressed because PBRM1 does not find its normal interaction partners in PBAF. The interactions between endogenous proteins also need to be demonstrated in ccRCC cell lines. The authors should also comment on the fact that KDM5C mutations tend to occur under the PBRM1 mutated background (PMID 27751729). How can these observations be rationalized?</p><p>The authors show that knockdown of IRF9 leads to much larger xenograft tumours than control cells. Did they do similar experiments with STAT1 or STAT2? If not what is the explanation? If there is no caveat, they should also show that silencing of either STAT1 or STAT2 has the same tumour-promoting effect. Stable silencing of IRF9 clearly affects its own expression, but does it result in lower STAT1 and STAT2 expression? Can the authors demonstrate that down-regulated IRF9 expression is maintained during tumour growth and in the endpoint tumours?</p><p>The authors show increased immune-infiltrate in the IRF9 knockdown cells, but only a mild increase in KI67 staining. If there is no strong increase in proliferation, why are the tumours so much bigger? Are the differences due to ISGF3 affecting apoptosis and/or senescence? This should be clarified. Similarly, overexpression of IRF9 and STAT2 strongly inhibits tumour growth, is this accounted for by decreased proliferation, or increased apoptosis/senescence?</p><p>Some important controls are missing: Figure 5F do not show knockdown of KDM5C and PBRM1 by western blot; Figure 6A and 6C do not show knockdown of SETD2 by western blot (RT-PCR shows minimal knock-down); Figure 6A, 6B and 6C have overexposed GAPDH signal, Figure 6 has no letter &quot;A&quot; in its tagline.</p><p>We suggest to repeat the experiment in Figure 5—figure supplement 4 in KDM5C knock-down.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.37925.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>All three reviewers thought that this was an interesting study with novel and relevant conclusions, but they found a number of important issues that require serious attention in any revised version.</p><p>The experiments performed in this study used established ccRCC cell lines. To verify that the observations are relevant for human ccRCC, the authors should use TCGA ccRCC datasets to investigate expression of ISGF3 in human ccRCC and its prognostic impact. They should use the TCGA dataset to test the hypothesis that tumors with no PBRM1, BAP1, SETD2 and KDM5C have differential expression of ISGF3 components. It is also essential to show by immunostaining that ISGF3 subunits are really down-regulated in sections form human ccRCC where the above genes are inactivated. It is critical that the mechanisms described here using model cells lines and xenograft tumours are verified in one way or another in panels of human ccRCC.</p></disp-quote><p>We thank the reviewers for the thoughtful comments and we agree that our mechanism need to be verified in human ccRCC panel. We first conducted analysis of TCGA dataset as suggested by the reviewers. However, in many cases, we did not find consistent correlations between mRNA levels of BAP1, PBRM1, KDM5C, SETD2 and ISGF3 components in the whole tumors (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>). There were a few positive correlations and one case of negative correlation. One possibility for these results is that the mRNA expression of ISGF3 components detected in TCGA is not primarily coming from cancer cells, but from other stromal cells which can distort the results. To investigate this, we analyzed the correlations between well-known immune and tumor cell markers (CD45 or PTPRC, CD3, CD8, etc. and CDH1, EPCAM) with ISGF3 subunits within the TCGA dataset. The graphs in Figure 9—figure supplement 1 clearly indicate that the mRNA expression of ISGF3 subunits in the TCGA dataset comes predominantly from immune cells as opposed to tumor cells (surrogated by EPCAM and E cadherin).</p><fig id="respfig1"><label>Author response image 1.</label><caption><title>The correlations between ISGF3 subunits and PBRM1, KDM5C, BAP1 or SEDT2 in the TCGA dataset.</title><p>Correlations between IRF9, STAT1 or STAT2 with indicated genes within the TCGA dataset. N = 533.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-37925-resp-fig1-v3.tif"/></fig><p>We also sought to confirm this with immunohistochemistry (IHC). We found that immune cells had much higher protein expression of ISGF3 subunits STAT2 than the normal or cancerous human kidney cells. On the same slide, the immune cells in lymph node, spleen and lung tissues were stained strongly positive with antibody against STAT2, but the normal and cancerous kidney tissue stained negative or very weakly (Figure 9—figure supplement 2A). Interestingly, in the lung tissue, the strong staining of STAT2 in the immune cells did not seem to significantly increase the staining intensity of the surrounding cells. Similar observation was made with IRF9 IHC (Figure 9—figure supplement 2B). Thus immune cells have much higher expression of ISGF3 subunits STAT2 and IRF9 than that in kidney cancer cells, and this could disrupt the detection of ISGF3 mRNA expression in the cancer cells. Since our hypothesis is that BAP1, PBRM1, KDM5C, SETD2 are critical to maintain the expression and/or function ofISGF3 subunits in the ccRCC cancer cells, we concluded that mRNA levels in the bulk tumors from the TCGA dataset are not suitable for our validation experiments.</p><p>To validate our hypothesis, we decided to examine the ISGF3 protein levels in ccRCC cancer cells with IHC and correlate their protein levels with the protein levels of BAP1, PBRM1, and SETD2. We have previously examined the protein levels of PBRM1 and SETD2 in a ccRCC tissue microarray (TMA) generated by our colleagues at Fox Chase Cancer Center in our previous publication (Jiang et al., 2016). This TMA includes 40 cases per tumor stage, and for each tumor 4 foci was chosen except for one case (total 638 foci). We probed the same TMA with antibodies against BAP1, IRF9 and STAT2. The staining ofBAP1 or IRF9 mostly occurs in the nucleus, while STAT2 staining is found in both cytoplasm and nucleus (Figure 9A). In many cases the protein expression levels of PBRM1, SETD2 or BAP1 correlated with that of STAT2 or IRF9 (Figure 9A). After scoring the samples and performing statistical analysis, the Spearman association analysis revealed that nuclear IRF9 and cytoplasmic STAT2 both significantly correlated with the expression of PBRM1, SETD2, or BAP1 (Figure 9B). The correlations were mostly statistically significant when all the foci were considered. In individual tumor stage or grade, the associations were mostly statistically significant as well. Interestingly, the loss of nuclear staining of IRF9 was associated with worse patient survival, consistent with a tumor suppressor role of ISGF3 (Figure 9C). The loss of cytoplasmic STAT2staining was not associated with worse patient survival (Figure 9D), suggesting that other ISGF3 components are the more dominant players in the human ccRCC. Consistent with this idea, the change of IRF9 protein in the TMA (Figure 9B) and in the cultured cells (Figures 5 and 6) tracked better with the changes of PBRM1, SETD2 or BAP1. Taken together, our data suggests that the links between PBRM1, SETD2 or BAP1 and ISGF3 are preserved in human ccRCC tumors. Wesley L. Cai, Geetha Jagannathan, Essel Dulaimi, Joseph R. Testa and Robert Uzzo contributed to this new analysis and are therefore added as co-authors.</p><disp-quote content-type="editor-comment"><p>The authors report that KDM5C and PBRM1 physically interact. Figure 4 shows that expression of FLAG-PBRM1 can precipitate endogenous KDM5C, but the opposite has not been shown by transfecting FLAG-KDM5C to pull down endogenous PBRM1. This should be further investigated. PBRM1 is a well characterized subunit of the PBAF complex. The results presented here suggest that KDM5C associates with PBAF through interactions with PBRM1. This is a potentially important finding, but should be confirmed. The authors should investigate whether tagged PBRM1 co-precipitates other subunits of the PBAF complex and they should verify whether tagged KDM5C can precipitate additional subunits of the PBAF complex. In particular, they should exclude the possibility that these proteins interact when overexpressed because PBRM1 does not find its normal interaction partners in PBAF. The interactions between endogenous proteins also need to be demonstrated in ccRCC cell lines. The authors should also comment on the fact that KDM5C mutations tend to occur under the PBRM1 mutated background (PMID 27751729). How can these observations be rationalized?</p></disp-quote><p>We thank the reviewers for your suggestion. We performed a series of experiments as the reviewers suggested. Flag-KDM5C was able to pull down endogenous PBRM1 along with BRG1 and BAF170, the catalytic and structural subunits of PBAF complex respectively (Figure 4C). Interestingly, it did not significantly co-IP BRD7 or BAF57, unlike that of Flag-PBRM1 (Figure 4B), suggesting that Flag-KDM5C pulled down a partial PBAF complex. Moreover, the endogenous PBRM1 also pulled down the endogenous KDM5C in human embryonic kidney (HEK) 293T cells along with the other PBAF subunits (Figure 4D), suggesting that they do exist in one complex in kidney cells and it is not an artifact due to over-expression. The exact mechanism of this interaction and it impact on the functions of PBRM1 and KDM5C await further investigation.</p><p>As to the co-occurrence of mutations in PBRM1 and KDM5C, we stated that “undoubtedly each TSG has its own unique tumor suppressing functions so each carries different prognosis for the patients” in our Discussion. It is possible that the unique tumor suppressor functions of PBRM1 and KDM5C are synergistic so their mutations are selected in the same cells during tumor development. This point has been added to the Discussion.</p><disp-quote content-type="editor-comment"><p>The authors show that knockdown of IRF9 leads to much larger xenograft tumours than control cells. Did they do similar experiments with STAT1 or STAT2? If not what is the explanation? If there is no caveat, they should also show that silencing of either STAT1 or STAT2 has the same tumour-promoting effect. Stable silencing of IRF9 clearly affects its own expression, but does it result in lower STAT1 and STAT2 expression? Can the authors demonstrate that down-regulated IRF9 expression is maintained during tumour growth and in the endpoint tumours?</p></disp-quote><p>This is a great suggestion and we agree that it is important to examine whether the suppression of STAT1 or STAT2 would boost tumor growth. We stably suppressed the expression of either STAT1 or STAT2 in 786-O cells then performed xenograft analysis. In both cases, the tumors were significantly bigger than the ones made by the control cells (Figure 7—figure supplement 3). We also found that IRF9 suppression did not suppress the expression of other subunits of ISGF3 (Figure 7—figure supplement 2A), and IRF9 suppression was maintained in the endpoint tumors (Figure 7—figure supplement 2B). The tumors made with the control cells were very small even at the end point, so it was not practical to examine IRF9 suppression during tumor growth.</p><disp-quote content-type="editor-comment"><p>The authors show increased immune-infiltrate in the IRF9 knockdown cells, but only a mild increase in KI67 staining. If there is no strong increase in proliferation, why are the tumours so much bigger? Are the differences due to ISGF3 affecting apoptosis and/or senescence? This should be clarified. Similarly, overexpression of IRF9 and STAT2 strongly inhibits tumour growth, is this accounted for by decreased proliferation, or increased apoptosis/senescence?</p></disp-quote><p>Thank for your suggestion and we have conducted several experiments to address these. However, we do not have a definitive answer to why the tumors were much bigger after the suppression of ISGF3 subunits. The apoptosis and proliferation, measured by cleaved caspase 3 and Ki-67 respectively, did not show great difference (Figure 5—figure supplement 2). We were unable to measure senescence in the tumor samples. Overexpression of IRF9 and STAT2 strongly inhibited tumor growth, and our examination did not reveal any major difference in cell proliferation or apoptosis either, at least within the tumors. Thus it is possible that higher ISGF3 activity recruited host immune cells to kill the cancer cells, which cannot be detected by the assays described above. If the attrition mostly happened at the outer layer, the dead cells might dissociate form the tumor and cannot be observed. It is also possible that other forms of cell death such as necrosis or ferroptosis happened within the tumor that we failed to detect with our methods. The exact mechanism will require further investigation with more sensitive methods to monitor the cancer cells and host cells including the immune cells. In light of this, we modified our discussion to “A possible mechanism is that heightened U-ISGF3 may attract more innate immune cells such as macrophages and NK cells to attack the tumors and curb tumor growth, as a previous report showed that over-expression of IFN-β recruited macrophages which suppressed tumor growth and metastasis in nude mice (Zhang, Lu and Dong, 2002). However, further studies to closely monitor the cancer and host cells are needed to provide a definitive answer to this question. “</p><disp-quote content-type="editor-comment"><p>Some important controls are missing: Figure 5F do not show knockdown of KDM5C and PBRM1 by western blot; Figure 6A and 6C do not show knockdown of SETD2 by western blot (RT-PCR shows minimal knock-down); Figure 6A, 6B and 6C have overexposed GAPDH signal, Figure 6 has no letter &quot;A&quot; in its tagline.</p></disp-quote><p>Thanks for pointing out these issues. We added western blots of knockdown of KDM5C and PBRM1 to Figure 5F.</p><p>We were able to detect SETD2 knockdown by western blot in 6A but not in 6C (probably due to low expression of SETD2 protein in RCC4 cells), and it was added as Figure 6—figure supplement 1.</p><p>Lighter GAPDH exposures were used replace the GAPDH blots in Figure 6A-C. Similar number of cells was used to generate lysates. Letter A in Figure 6A was added.</p><disp-quote content-type="editor-comment"><p>We suggest to repeat the experiment in Figure 5—figure supplement 4 in KDM5C knock-down.</p></disp-quote><p>As suggested, we performed the experiment and found that similar to PBRM1, KDM5C does not affect phosphorylation of ISGF3. We added these results to Figure 5—figure supplement 4.</p></body></sub-article></article>